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 Human Immunodeficiency Virus (HIV) central nervous system (CNS) disease 
remains a significant clinical issue in the post-antiretroviral therapy (ART) era. Although the 
severity of HIV CNS disease has decreased with ART, the prevalence has not changed. It is 
hypothesized that chronic inflammation in the CNS despite effective viral suppression is 
critical to the pathogenesis of HIV CNS disease. As one of the immune cells in the brain that 
is also chronically infected with HIV, microglia are of particular interest.  
 In this dissertation, we characterized chronic microglial immune activation in an 
SIV/pigtailed macaque model of HIV CNS disease. We characterized in this model the 
expression colony stimulating factor 1 receptor (CSF1R), a classic tyrosine kinase receptor 
that is constitutively expressed on cells of the myeloid lineage that is essential for the 
survival of microglia. Additionally, overexpression of CSF1R has been associated with 
several neurodegenerative diseases, including Alzheimer’s disease (AD) and amyotrophic 
lateral sclerosis (ALS). In animals with SIV encephalitis, we found that CSF1R was 
significantly elevated in brain compared to uninfected animals. Interestingly, CSF1R protein 
levels remained elevated in the brains of ART-suppressed SIV-infected animals, suggesting 
that CSF1R plays a role in the persistence of HIV CNS disease in the post-ART era.  
 We also characterized a similar receptor, triggering receptor expressed on myeloid 
cells 2 (TREM2). TREM2 is similarly associated with AD and ALS, and there is significant 
crosstalk between TREM2 and CSF1R via DNAX adaptor protein 12 (DAP12). 
Consequently, TREM2 and CSF1R have many of the same downstream signaling effects in 
microglia. While TREM2 and CSF1R both significantly increase in SIV encephalitis, 





TREM2 and CSF1R have unique roles in neuroinflammation, particularly in the context of 
chronic, suppressed SIV infection.  
 Finally, we performed a pilot pre-clinical drug trial in suppressed, SIV-infected 
pigtailed macaques with PLX3397, a small-molecule CSF1R inhibitor. PLX3397 was kept 
onboard after animals were released from ART. PLX3397 treatment reduced the number of 
microglia both in vitro and in vivo. While PLX3397 had no effect on plasma viral rebound, 
treatment prevented viral rebound in the cerebrospinal fluid of one animal. Additionally, 
PLX3397 treatment changed the morphology of the remaining microglia from an ameboid, 
activated state to a resting/surveilling state. The work presented in this dissertation provides a 
unique insight into the mechanisms of chronic inflammation in the CNS of SIV-infected 
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Human Immunodeficiency Virus 
 Human immunodeficiency virus (HIV) is one of the most prevalent infectious 
diseases, infecting approximately 37.9 million people worldwide as of 2018 (hiv.gov). 
Despite effective antiretroviral therapy, HIV continues to be a significant public health 
concern. In 2018, there were 1.1 million new HIV infections worldwide (hiv.gov). Although 
HIV most likely crossed the species barrier as early as 1930 (Korber et al. 2000), the HIV 
pandemic was first described in the early 1980s (Levy 2007).  
 HIV is a lentivirus that infects both CD4+ T lymphocytes and myeloid cells (Gonda 
et al. 1986; Barre-Sinoussi et al. 1983; Gallo et al. 1984). CD4+ T cell infection is one of the 
defining characteristics of clinical HIV disease. Without treatment, HIV causes CD4+ T 
lymphocyte depletion resulting in immune suppression and death approximately 8-10 years 
after initial infection if left untreated. Acquired immunodeficiency syndrome (AIDS), the 
end-stage disease of HIV infection, is defined as a CD4+ T lymphocyte count of less than 
200 cells/mL of blood accompanied by an AIDS-defining opportunistic infection (Groopman 
and Gottlieb 1983; AIDSinfo.nih.gov).  
 In order for HIV to infect a cell, it first binds to the host cell CD4 and a co-receptor—
either CCR5 or CXCR4 (Dalgleish et al. 1984; Choe et al. 1996). This binding leads to the 
fusion of the HIV envelope with the host cell membrane, releasing the viral capsid into the 
cytoplasm. The contents of the capsid are then released. The capsid contains the HIV 
genome—two single strands of RNA—and proteins required for reverse transcription 
(reverse transcriptase) and integration (integrase) of the HIV genome into the host DNA. 
Once in the cytoplasm, reverse transcriptase synthesizes complementary, double stranded 





is integrated into the genome. Once the viral DNA is integrated into the host genome, new 
viral RNA and proteins are able to be synthesized by the host transcription and translation 
machinery (Freed 2001). Importantly, immune activation, particularly via the NF-kB 
pathway, is known to activate transcription of HIV genes integrated in the host genome (Duh 
et al. 1989). These infected cells can then generate new fully packaged virions that can be 
released from the host cell by another viral protein, protease. HIV protease is also essential in 
the maturation of the released virion; the mature virion can then infect new cells (Freed 
2001).  
 Antiretrovirals have been successful in targeting several key points throughout 
infection that results in the reduction of detectable HIV in the plasma. For the initial infection 
of a host cell, drugs can prevent the binding of the virion to the receptors on the host cell 
(CCR5 antagonists), and others prevent the fusion of the viral envelope with the host cell 
membrane. Other antiretrovirals target reverse transcriptase (nucleoside/non-nucleoside 
reverse transcriptase inhibitors—N/NNRTIs), integrase, or protease. A treatment plan 
consisting of a combination of these antiretrovirals can successfully suppress viral 
replication, resulting in undetectable levels of virus in the plasma while decreasing the risk of 
developing resistance mutations (Pau and George 2014).  
Since the development of antiretroviral therapy (ART), HIV-infected individuals are 
now able to live near normal lifespans (Antiretroviral Therapy Cohort 2017). However, ART 
is not curative. Although only a small proportion of CD4+ T cells are infected, a subset of 
these cells can be incredibly long-lived. HIV can readily infect activated CD4 T cells. In 
many cases, the infection of an activated CD4+ T cell will result in the death of the cell along 





is in the process of transitioning to a memory cell, the virus can integrate its genome into the 
cell without resulting in the death of the host cell. While some virus can be produced from 
these cells, active viral replication is quickly shut down as the cell transitions to a quiescent 
memory cell. These long-lived, infected cells can remain dormant in an individual and ART 
cannot target these cells because ART targets active viral replication. If the cell is 
reactivated, it can then also activate viral replication, producing more virus to then infect 
other cells (Sengupta and Siliciano 2018).  
 Because of these characteristics, memory CD4+ T cells are considered the major cell 
type that makes up the latent reservoir. However, HIV also infects monocytes and tissue 
macrophages. Tissue macrophages can live for longer periods of time and can harbor 
replication competent virus in the context of ART. In a simian immunodeficiency virus 
(SIV)/pigtailed macaque model where animals were fully suppressed with ART for at least 
six months and up to 18 months, SIV DNA could be detected in macrophages isolated from 
the spleen and lung, as well as in peripheral blood monocytes (PBMCs). These levels of SIV 
DNA were comparable to those found in CD4+ T cells. Additionally, replication competent 
virus was isolated from macrophages taken from the spleen, lung, and blood (Abreu et al. 
2019). This suggests that macrophages can serve as an additional latent reservoir. 
 It is clear that ART will not significantly address the issue of the latent reservoir. It is 
estimated that the latent reservoir in an HIV-infected individual that is fully suppressed 
would take approximately 74 years to be eliminated (Siliciano et al. 2003). Consequently, 
new therapies need to be developed that target and eliminate the latent reservoir. One cure 
strategy is ‘latency reversal’. It is thought by treating patients with a latency reversing agent 





without the activation of the infected cell. This would allow the infected cell to be recognized 
and eliminated by the immune system (Bashiri et al. 2018). However, LRAs have not been 
particularly efficient in clearing the latent reservoir. This may be due to a combination of an 
inability to activate virus production in all latently infected cells, off-target effects that 
prevent the ability of CD8+ T cells from killing infected cells, and an inability of latently-
infected cells to present enough viral antigen to stimulate CD8+ T cells (Ke et al. 2018; 
Clutton and Jones 2018). LRAs have also been shown to cause increased inflammation in the 
brain of SIV-infected rhesus macaques, suggesting that LRAs could cause significant 
neuronal damage (Gama et al. 2017). 
 Therapeutic vaccines have also been considered as a potential cure. Because of HIV’s 
high mutation rate, antibody responses to HIV have largely been ineffective. However, the 
discovery of broadly-neutralizing antibodies against HIV provided evidence that the 
development of a vaccine against HIV may be possible (Bonsignori et al. 2012). It is thought 
that an effective therapeutic vaccine given to an HIV-infected patient that is fully suppressed 
would stimulate an appropriate immune response. With subsequent activation of the viral 
reservoir through LRA treatment, the individual’s immune system would be able to eliminate 
infected cells and neutralize infectious virus released from those cells (Mylvaganam et al. 
2015). Although a vaccine is theoretically possible, an effective vaccine has yet to be 
discovered.  
As the field looks toward cure strategies, it is important to consider all possible 
sources of HIV infection. Although there is still some debate, there is significant evidence 
suggesting that cells of the myeloid lineage constitute a latent reservoir for HIV (Wong et al. 





macrophages is thought to drive these chronic organ-specific diseases. It is hypothesized that 
as the HIV-infected population continues to age, clinicians will begin to see an increase in 
HIV-associated organ-specific diseases, including CNS, cardiovascular, and gastrointestinal 
disease (High et al. 2012). Therefore, understanding the viral dynamics of chronic HIV 
infection of myeloid cells is critical to not only treating chronic organ disease, but also to 
curing HIV infection.  
 
HIV-associated central nervous system (CNS) disease 
 In the brain, the primary cells infected with HIV are parenchymal microglia and 
perivascular macrophages (Abreu et al. 2019; Wallet et al. 2019). There are several ways that 
HIV may establish CNS infection. HIV enters the brain either through infected CD4+ T cells 
or monocytes trafficking into the brain, such as CD4+ T cells or myeloid cells, via 
diapedesis. Free HIV virions can also enter the brain directly through the blood-brain barrier 
or the cerebrospinal fluid (CSF)-brain barrier via transcytosis. This process is highly 
dependent on pericyte responses to inflammatory cytokines (Dohgu and Banks 2013).  Either 
of these pathways leads to direct infection of resident perivascular macrophages and 
microglia (Levy 2007; Williams et al. 2013). It is thought that this infection and subsequent 
immune responses drive CNS disease.   
HIV associated neurocognitive disease (HAND) can be broken down into three 
clinical subsets: asymptomatic neurocognitive impairment (ANI), mild neurocognitive 
disorder (MND), and HIV associated dementia (HAD). ANI is characterized by decreased 
function in two or more neurocognitive domains that is apparent during neurocognitive 





that directly decrease quality of life. HAD presents similarly to other forms of dementia, 
where neurocognitive function is severely impaired (Saylor et al. 2016). 
Before the introduction of ART, approximately half of HIV-infected individuals 
developed CNS impairment, with a significant portion of these individuals developing HAD 
(20%). The introduction of ART has significantly decreased the prevalence of HAD to 2% of 
the HIV-infected population. In spite of this reduction in severity, HAND remains a 
significant consequence of HIV-infection; still today, half of the HIV-infected population has 
neurocognitive impairment (Saylor et al. 2016). This suggests that although viral replication 
is a significant factor in the development of HIV CNS disease, it is not the sole cause.  
There is evidence in animal models and in fully suppressed HIV-infected individuals 
that there is ongoing inflammation in the brain. This has been related to poorer cognitive and 
motor function (Saylor et al. 2016; Montoya et al. 2019). In addition to ongoing 
neuroinflammation, it is hypothesized that chronic HIV infection alters the homeostatic 
baseline of neuroimmune cells, including microglia and astrocytes. It has been shown in 
microglia that chronic HIV infection alters microglial metabolism, apoptosis, and immune 
activation (Chen et al. 2018). Consequently, microglia play an essential role in the 
development of HIV CNS disease.  
 
The role of microglia in HIV CNS disease 
 Microglia are a resident immune cell in the brain and comprise approximately 10% of 
CNS cells. Although closely related to bone marrow-derived macrophages, microglia 





enter the CNS early during development, anywhere from 4 to 24 gestational weeks; in mice, 
this migration occurs at E9 (Menassa et al. 2018; Thion et al. 2018).  
 As a glial cell, microglia are essential in maintaining CNS health. During 
development, microglia assist in the development of neuronal networks through promoting 
synaptogenesis, neuronal spine pruning, and the survival of neuronal precursor cells. In 
adulthood, microglia continue to support neuron connections as well has assisting in the 
formation of new networks and the destruction of redundant pathways (Sominsky et al. 
2018). Beyond directly supporting neuronal networks, microglia serve as a CNS resident 
immune cell. Microglia are innate immune cells, phagocytosing foreign elements including 
pathogens, presenting antigen to adaptive immune cells, and secreting inflammatory 
cytokines (Colonna and Butovsky 2017).  
Microglia have been implicated in several neurodegenerative diseases, including 
Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and 
HIV CNS disease (Cartier et al. 2014). Considering microglia are a major immune cell in the 
brain and the primary CNS cell type that is infected with and can produce infection-
competent HIV, microglia appear to be essential in the development of HIV CNS disease 
(Saylor et al. 2016; Williams et al. 2014). However, the exact mechanism of how microglia 
cause neurodegeneration in the context of HIV infection is not clear, especially considering 
that individuals continue to develop HIV CNS disease in spite of effective viral suppression.  
It is hypothesized that chronic inflammation and microglial activation are major 
contributors to the pathogenesis of HIV CNS disease. While viral replication is inhibited, 
there have been reports showing that viral proteins are still released from infected cells 





resulting in chronic microglial activation (Saylor et al. 2016). Further, there is histologic 
evidence that in fully suppressed pigtailed macaques, microglial morphology resembles a 
more activated state (Figure 2-4). These viral proteins can also stimulate astrocytes, which 
release glutamate, resulting in excitotoxic neuronal damage (Saylor et al. 2016). 
Consequently, modulating the immune response and clearing the latent reservoirs are key 
components of treating HIV CNS disease.  
 
SIV/Pigtailed Macaque Model of HIV CNS Disease 
 To study the contribution of microglia to the pathogenesis of HIV-associated CNS 
disease, we utilize the SIV/pigtailed macaque model of HIV CNS disease. Simian 
immunodeficiency virus (SIV) is a lentivirus closely related to HIV. There is evidence that a 
strain of SIV (SIVchpz) crossed the species barrier to become HIV-1 in the 1930s (Korber et 
al. 2000). SIV naturally infects numerous African non-human primate species, including 
chimpanzees (SIVchpz) and sooty mangabeys (SIVsmm). Despite active viral replication, SIV 
does not cause disease in these natural hosts. However, SIV is able to cause disease in non-
native hosts. It is thought that SIVchpz crossed the species barrier and established HIV-1 
infection in humans as it is most closely related to HIV-1, while SIVsmm is closely related to 
HIV-2 (Hahn et al. 2000; Silvestri et al. 2007; Van Heuverswyn and Peeters 2007).  
 Similar to human infection, when SIV infects non-native hosts, such as Asian 
macaques, the disease shares many characteristics with HIV infection in humans (Hahn et al. 
2000; Silvestri et al. 2007; Van Heuverswyn and Peeters 2007). Consequently, rhesus 
macaques (Macaca mulatta) and pigtailed macaques (Macaca nemestrina) are often utilized 





In the SIV/pigtailed macaque model, pigtailed macaques are inoculated with two 
strains of SIV: SIV/DeltaB670 and SIV/17E-Fr. SIV/DeltaB670 is an immunosuppressive 
swarm. This virus depletes CD4+ T-cells and infects myeloid cells. SIV/17E-Fr, on the other 
hand, is a molecular clone with specific mutations in the env, nef, and 3’LTR regions of the 
viral genome that confer macrophage tropism and the ability to replicate within the CNS 
(Beck et al. 2017). Interestingly, this same infection paradigm in rhesus macaques, the 
typical animal utilized in SIV studies, does not produce the same consistent CNS 
presentation (Beck et al. 2015).  
 Peak virus can be detected in both plasma and CSF at 12 days post-infection. CSF 
viral loads tend to be a log lower than plasma viral loads. After acute infection, viral loads in 
plasma and CSF decrease, but not to the same levels seen in HIV-infected patients who are 
not on antiretroviral therapy. This allows for an accelerated model of HIV infection. 
Approximately 60% of infected pigtailed macaques will develop SIV CNS disease within 84 
days of infection, the timepoint when all animals have AIDS-defining conditions (Beck et al. 
2015). CNS disease is characterized by macrophage-predominant perivascular cuffs and 
microglial giant cells. These lesions overlap with active SIV replication in these cells (Beck 
et al. 2017).  
 An additional benefit of this model is that animals can be treated with current 
standard of care antiretrovirals. In our model, PMPA (9-(2-
phosphonomethoxypropyl)adenine), Emtricitabine (FTC), and Dolutegravir are injected 
subcutaneously daily. Treatment is started 12 days post-infection and results in successful 
suppression, defined as plasma viral load being below 100 copies/mL of virus in both the 





In this context, we are able to study chronic SIV infection and the resultant organ-specific 
diseases, particularly those of the CNS under ART (Beck et al. 2017).  
 Beyond studying chronic suppressed SIV infection, we can also study viral rebound 
dynamics in this model by removing ART akin to structured treatment interruptions in HIV 
patients (Papasavvas et al. 2004). In this protocol, animals are released from ART and viral 
dynamics are monitored by tracking plasma and CSF viral loads over time. Animals are 
euthanized when they reach viral set-point with three consecutive measurements of plasma 
viral load within one log of each other. We can then identify tissue and cellular sites that the 
virus replicates to study the immunologic impacts of rebound active viral replication.   
 
Project Overview 
 For my dissertation, I characterized chronic microglial activation in the context of 
HIV CNS infection in the SIV/pigtailed macaque ART model.  
In chapter II, I characterized colony stimulating factor 1 (CSF1R) and its two ligands, 
colony stimulating factor 1 (CSF1) and IL34 in the SIV/pigtailed macaque model. Colony 
stimulating factor 1 receptor (CSF1R) is a classic tyrosine kinase receptor constitutively 
expressed on cells of the myeloid lineage. In the brain, the primary cells expressing this 
receptor are microglia (Stanley and Chitu 2014). CSF1R signaling is essential for the 
survival, proliferation, and activation of microglia; if CSF1R receptor signaling is prevented 
either with a small molecule inhibitor or by knocking out the gene, microglia are depleted 
(Figure 1-2; Elmore et al. 2014; Erblich et al. 2011). Increased CSF1R expression has been 
seen in multiple neurodegenerative diseases, including AD, ALS, and prion diseases 





increased in both grey and white matter in SIV-infected pigtailed macaque frontal cortex 
after 84 days of infection whereas IL34 expression did not change (Figure 2-2). CSF1R 
protein levels were also significantly increased in the white matter of these same animals as 
shown by immunohistochemistry (Figure 2-4) and ELISA (Figure 2-5). Interestingly, 
CSF1R protein remained elevated in fully suppressed SIV-infected pigtailed macaque frontal 
cortex. As microgliosis does not occur in fully suppressed SIV-infected pigtailed macaques, 
this increase in CSF1R is not thought to be due to an increase in microglial number. Rather, 
the increase in CSF1R protein is likely due to an increase at the single-cell level. This 
suggests that although SIV replication is inhibited, microglia are in a different state of 
immune activation. This could represent microglial priming or a continued activated state.  
In chapter III, I characterized triggering receptor expressed on myeloid cells 2 
(TREM2) mRNA and protein expression in this same model. TREM2, much like CSF1R, is 
constitutively expressed on cells of the myeloid lineage, and in the brain is primarily 
expressed on microglia. TREM2 has many of the same downstream effects as CSF1R: cell 
activation, survival, and proliferation (Figure 1-3; Yeh et al. 2017). In spite of this, we found 
that while TREM2 and CSF1R mRNA expression are highly correlated in this model (Figure 
3-2), they are not correlated at the protein level (Figure 3-4). Additionally, after animals 
were released from antiretroviral treatment to study viral rebound, TREM2 protein remained 
at baseline, while CSF1R protein remained elevated from baseline with several animals 
expressing much higher levels of CSF1R than in fully suppressed animals (Figure 3-6). 
While both TREM2 and CSF1R protein increase with SIV encephalitis, we hypothesize that 
the increase in TREM2 protein is due to an increase in microglial cell number. This is 





pigtailed macaques. However, CSF1R protein levels remain elevated in these animals, 
suggesting that this increase is happening at the single-cell level (Figure 1-4). Consequently, 
we hypothesize that CSF1R may be a marker of microglial priming, wherein after initial 
responses, microglia are more easily activated and have stronger responses upon secondary 
stimulation (Perry and Holmes 2014). 
Finally, in chapter IV, I determined the efficacy of the CSF1R small molecule 
inhibitor, PLX3397 in our SIV/pigtailed macaque model. In vitro, PLX3397 effectively 
killed primary pigtailed macaque microglia (Figure 4-3). In vivo, 165mg/kg of PLX3397 
prevented viral rebound in the cerebrospinal fluid in one of two animals, while it had no 
effect on viral rebound in plasma (Figure 4-5). Additionally, microglia isolated at necropsy 
from this animal did not release detectable virus ex vivo by quantitative PCR. Therefore, 








Figure 1-1. Overview of the HIV infection lifecycle. (1) HIV initially binds to the host cell 
via receptors. This triggers (2) fusion and the release of viral RNA. Once in the cytoplasm, 
(3) reverse transcription of viral RNA to double-stranded DNA occurs. This is then shuttled 
to the nucleus and is (4) integrated into the host genome. Once integrated, (5) transcription of 
viral RNA is possible. (6) Translation of viral proteins is followed shortly thereafter by (7) 
virion assembly. The virion is then able to (8) bud off from the host cell and is (9) released. 
After release, the virion undergoes further maturation. The mature virion is then capable of 











































Figure 1-2. CSF1R signaling in microglia. After the binding of one of its ligands (CSF1 
pictured), CSF1R undergoes autophosphorylation. This signaling results in cell survival, 
proliferation, and differentiation. We hypothesize that CSF1R signaling may also impact 







Figure 1-3. TREM2 and CSF1R signaling interact via DAP12 in microglia. TREM2 and 
CSF1R signaling intersect at the signal transduction receptor DNAX-activating protein of 12 
kDa (DAP12). Consequently, there is significant overlap between the downstream signaling 
effects of TREM2 and CSF1R including microglial survival and proliferation. We 
hypothesized that TREM2 and CSF1R signaling would also affect CNS immune regulation 













Figure 1-4. Summary of the effect of chronic immune stimulation on TREM2 and 
CSF1R during SIV infection. TREM2 and CSF1R protein increases with inflammation and 
microgliosis. With chronic immune stimulation, where microglial number returns to baseline, 
TREM2 protein levels return to baseline. However, CSF1R protein levels remain elevated 



























































Chronic microglial activation and associated neuroinflammation are key factors in 
neurodegenerative diseases including HIV-associated neurocognitive disorders. Colony 
stimulating factor 1 receptor (CSF1R)-mediated signaling is constitutive in cells of the 
myeloid lineage, including microglia, promoting cell survival, proliferation, and 
differentiation. In amyotrophic lateral sclerosis and Alzheimer’s disease, CSF1R is 
upregulated. Inhibiting CSF1R signaling in animal models of these diseases improved 
disease outcomes. In our studies, CNS expression of the CSF1R ligand, colony stimulating 
factor 1 (CSF1) was significantly increased in an SIV/macaque model of HIV CNS disease. 
Using a Nanostring nCounter immune panel, we found CSF1 overexpression was strongly 
correlated with upregulation of microglial genes involved in antiviral and oxidative stress 
responses. Using in situ hybridization, we found that CSF1R mRNA was only present in 
IBA1 positive microglia. By ELISA and immunostaining with image analysis, SIV-infected 
macaques had significantly higher CSF1R levels in frontal cortex than uninfected macaques 
(P = 0.018 and P = 0.02, respectively). SIV-infected macaques treated with suppressive ART 
also had persistently elevated CSF1R similar to untreated SIV-infected macaques. 
Coordinate upregulation of CSF1 and CSF1R expression implicates this signaling pathway in 








Microglia, comprising parenchymal microglia and perivascular macrophages in the 
CNS, play a central role in multiple chronic neurodegenerative diseases including 
Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and HIV-Associated 
Neurocognitive Disorder (HAND) (Lall and Baloh 2017; Ransohoff and El Khoury 2015; 
Saylor et al. 2016; Williams et al. 2014). In these diseases, immune activation of microglia 
may be pivotal in regulating neuroinflammation, a process likely dependent on disease stage 
(Dheen, Kaur, and Ling 2007).  
Knockout and inhibition studies in rodent models have shown that colony stimulating 
factor 1 receptor (CSF1R) signaling is essential for microglial survival, proliferation, and 
differentiation (Elmore et al. 2014; Erblich et al. 2011; Sherr 1990; Stanley and Chitu 2014). 
Upregulation of CSF1R by microglia has been identified in AD, ALS, and other 
neuroinflammatory diseases including prion diseases (Akiyama et al. 1994; Gomez-Nicola et 
al. 2013; Mitrasinovic and Murphy 2003). Of particular note, CSF1R blockade improved 
disease outcomes in mouse models of late-stage AD and ALS (Dagher et al. 2015; Martinez-
Muriana et al. 2015), demonstrating that microglial immune responses can be either 
beneficial or harmful depending on context. 
CSF1R has two known ligands: colony stimulating factor 1 (CSF1) and IL34. Both 
ligands are expressed in the CNS, but IL34 appears to be more essential to homeostatic 
regulation in specific areas of the brain, including the cerebral cortex, basal ganglia, and 
hippocampus (Zelante and Ricciardi-Castagnoli 2012). Interestingly, previous work suggests 





al. 2016; Gerngross and Fischer 2015) and therefore may be the more important CSF1R 
ligand in chronic neurodegeneration (De et al. 2014). 
Persistent CNS inflammation including microglial immune activation is thought to 
drive the pathogenesis of HAND (Saylor et al. 2016; Spudich 2016). HIV can infect cells of 
the myeloid lineage, including microglia, thereby stimulating or dysregulating the 
neuroimmune response in HAND (Saylor et al. 2016; Williams et al. 2014). Previous work in 
a rhesus macaque SIVmac251 model of HIV CNS infection has shown that increased CSF1 
expression occurs in CD163+ cells (Gerngross et al. 2015), cells that accumulate in 
perivascular cuffs and microglial nodules in SIV encephalitis (Gerngross and Fischer 2015).   
In this report, we show that CSF1 expression increased in the SIV/pigtailed macaque 
model of HIV CNS disease whereas IL34 expression did not change with SIV infection. 
CSF1 overexpression was significantly correlated with microglial genes involved in the anti-
viral response to SIV, and in response to oxidative stress. In addition to upregulation of the 
ligand CSF1, CSF1R expression in microglia also increased with infection, implicating the 







Materials and Methods 
Animals 
All experiments were performed on samples collected at necropsy from male juvenile 
pigtailed macaques (Macaca nemestrina). Samples were stored at -80°C prior to use. 
Animals were either (1) mock inoculated with Lactated Ringers Solution (LRS), (2) 
inoculated intravenously with the neurovirulent molecular clone SIV/17E-Fr and the 
immunosuppressive swarm SIV/DeltaB670 (SIV), or (3) SIV inoculated and treated with an 
ART regimen (SIV + ART) (Beck, Kelly et al. 2015; Beck et al. 2017; Beck, Queen et al. 
2015). Untreated SIV-infected animals were euthanized at 21 days post-infection (p.i.), or 84 
days p.i. unless the animal began showing symptoms of AIDS before the end point of the 
respective study. SIV-infected animals that were treated with ART (n=7) were fully 
suppressed in CSF and plasma by 56 days p.i., and were euthanized 180 days p.i., after 
approximately 120 days of ART suppression. SIV+ART animals were treated daily with a 
subcutaneous injection of 2.5 mg/kg Dolutegravir (ViiV Healthcare US, Raleigh, NC), 20 
mg/kg PMPA, and 40 mg/kg FTC (Gilead, Foster City, CA). Four of the seven treated 
animals were also given 20 mg of oral Maraviroc (ViiV Healthcare US, Raleigh, NC) daily. 
This difference in treatment regimen did not cause a significant difference in time to 
suppression in either CSF or plasma; there was also no significant difference in the CNS-
specific measures performed for this study. As this study was conducted retrospectively, all 
samples were not available for each animal, hence minor variation in animal group size in 
different experiments. 
At necropsy, all animals were perfused with phosphate-buffered saline. Brains were 





10% neutral buffered formalin (NBF), Streck tissue fixative (STF), or flash-frozen. Both 
basal ganglia and frontal cortex sections were utilized in this study. All animal studies were 
approved by the Johns Hopkins Animal Care and Use Committee.  
 
RNA measurements 
The Nanostring nCounter gene expression panel used for analysis included 249 genes 
of interest (Meulendyke et al. 2014). The geometric means of four housekeeping genes were 
used to normalize counts.  mRNA counts of genes of interest were then normalized to the 
geometric mean of the four housekeeping genes (GAPDH, RPL13A, SDHA, and TBP), as 
well as the geometric mean of spike-in controls. The limit of detection was determined by 
taking the mean of three negative controls plus two standard deviations as detailed previously 
(Meulendyke et al. 2014). RNA for this panel was isolated from basal ganglia sections 
harvested at necropsy from uninfected and SIV-infected (84 days p.i.) macaques as described 
previously (Meulendyke et al. 2014). 100ng of RNA was used for input. 100ng of MS2 
phage RNA (Roche, Basel, Switzerland) run in triplicate served as a negative control.   
For quantitative RT-PCR, RNA was isolated from grey and white matter frontal 
cortex flash frozen at -80°C. Tissue was placed in Fast RNA tubes with lysing matrix D (MP 
Bio, Solon, OH) and RNA STAT-60. Each tube was homogenized for 30 seconds using the 
Fast Prep-24 homogenizer (MP Bio, Solon, OH). Tubes were then incubated at room 
temperature for 5 minutes. 200µL of chloroform was added. Tubes were then shaken for 15 
seconds and incubated at room temperature for three minutes. Samples were then centrifuged 
at 14,000 rpm for 15 minutes at 4°C. The aqueous portion was then added to a fresh tube 





tubes were centrifuged at 14,000 rpm for 15 minutes at 4°C and the isopropanol was 
removed. The pellet was then washed in ice-cold 70% ethanol. Tubes were centrifuged at 
10,000 rpm for 5 minutes at 4°C and the ethanol was removed. The pellet was then allowed 
to air dry for approximately 15 minutes at room temperature. RNA isolation was completed 
using the Qiagen RNeasy kit (Qiagen, Frederick, MD) according to the manufacturer’s 
protocol. Quality and concentration of the isolated RNA was determined using Nanodrop. 
One microgram of RNA was added to each RT reaction. The High Capacity cDNA 
reverse transcription kit was used (Applied Biosystems, Carlsbad, CA) with samples run in 
duplicate with a no reverse transcriptase control for each as well as no template controls. 
Reverse transcription was performed with the PTC-200 (MJ Research, Port Republic, NJ). 
The samples were held at 25°C for 10 minutes to anneal, then 37°C for 120 minutes for 
reverse transcription, and finally 85°C for 5 minutes to inactivate the reverse transcriptase. 
Samples were held at 4°C overnight before being stored at -20°C.  4µL of cDNA was used 
for qPCR per sample. Each was run in duplicate with no template controls and no reverse 
transcriptase controls. The TaqMan ® Universal Master Mix II or the Gene Expression 
Master Mix was used (Applied Biosystems, Carlsbad, CA) with CSF1 (cat. 
Rh02621778_m1) and IL34 (cat. Rh01050928_m1) probes (Biosystems, Carlsbad, CA); all 
counts were normalized to 18S ribosomal RNA and reported as DDCt (cycle threshold). 
 
CSF1R cellular localization and measurements 
CSF1R RNA was visualized in cells by in situ hybridization. Combined CSF1R 
ISH—Iba-1 IHC double-staining was performed on frontal cortex using the Leica Bond RX 





hours and embedded in paraffin before sectioning at 5 µM. A CSF1R probe (cat. 310818, 
Advanced Cell Diagnostics, Newark, NJ) was used with the RNAScope® 2.5 LS Assay-RED 
Kit according to manufacturer’s protocol. Epitope retrieval was performed by heating to 
95°C for 20 minutes in EDTA-based ER2 buffer (Leica Biosystems, Richmond, IL). Anti-
Iba-1 antibody (cat. 019-19741, Wako, Richmond, VA) was diluted 1:500. Slides were 
counterstained with hematoxylin.  
CSF1R IHC was performed using indirect, alkaline phosphatase-based 
immunostaining on STF fixed frontal cortex sections using the Bond RX automated system 
with the Bond Polymer Refine Red kit (Leica Biosystems, Richmond, IL). Each slide was 
heated to 95°C for 20 minutes in EDTA-based ER2 buffer for heat-induced epitope retrieval. 
Anti-CSF1R (Santa Cruz Technologies, cat. sc-692, Santa Cruz, CA) was used as the 
primary antibody (1:50 dilution). Positive immunoreactivity was visualized by labeling with 
the Bond Polymer Refine Red kit (alkaline phosphatase) (Leica Biosystems, Richmond, IL). 
Slides were counterstained with hematoxylin. Image acquisition and analysis to measure 
CSF1R was performed with Nikon Elements software (Nikon, Melville, NY) by generating 
composite images composed of 3X12 200X high power fields encompassing both grey and 
white matter. A threshold for positive staining was established using a set of blinded images 
and applied to all images to calculate the area fraction (%ROI) representing positive staining. 
Regions of interest (ROIs) were drawn around grey and white matter separately. The median 
size of the areas analyzed for grey and white matter were 2.6 X 106 µm2 and 8.6 X 105 µm2 
respectively.  
 CSF1R ELISAs were performed on frontal cortex homogenates prepared from 50 mg 





MA) with added protease and phosphatase inhibitors (Roche, Basel, Switzerland) and 
homogenized with a hand-held homogenizer. 300µL of 1X cell lysis buffer was then added 
for a total of 500µL. Samples were then sonicated using a cup sonicator five times for 20 
seconds with 15 second breaks. Tubes were then rotated at 4°C for two hours and pelleted at 
4°C for 5 minutes at 14K rpm. Supernatant was collected and used. Protein concentrations of 
these homogenates were determined using the QubitTM protein assay kit according to 
manufacturer’s protocol (Invitrogen, Carlsbad, CA). These concentrations were validated by 
running 5µg of protein of each sample on a Criterion Stain FreeTM Tris-HCL 4-20% 
separation gel and read using the Gel Doc EZ ImagerTM (Bio Rad, Hercules, CA). The 
Biomatik Human MCSFR ELISA kit (Biomatik, Wilmington, DE) was used per 
manufacturer’s protocol. 30µg of protein from each sample were added in duplicate to 
antibody pre-coated wells. TMB solution was allowed to develop for 15 minutes at room 
temperature. Wells were read at 450nm immediately after the addition of stop solution.  
Statistical Analysis 
 Prism was used to calculate all statistics except the Benjamini-Hochberg correction, 
which was applied using the p.adjust function in R. The Benjamini-Hochberg false discovery 
rate was set to 0.05. Non-parametric statistical tests were used (Mann-Whitney and Spearman 











CSF1 expression increased in SIV-infected pigtailed macaques. 
Alterations in expression of both CSF1R ligands CSF1 and IL34 have been reported 
in vivo in an SIVmac251/rhesus macaque model and with HIV infection in vitro (Gerngross 
and Fischer 2015; De et al. 2014; Gruber et al. 1995; Kalter et al. 1991). To evaluate CSF1 
expression in the SIV/pigtailed macaque model of HIV CNS disease, we analyzed a 
Nanostring nCounter dataset including 123 genes above the limit of detection (Supplemental 
Table 1) obtained using RNA isolated from basal ganglia from SIV-infected macaques 
sacrificed 21 days p.i. (n = 6) or 84 days p.i. (n = 13). Uninfected pigtailed macaques (n = 
10) served as controls (Meulendyke et al. 2014). CSF1 mRNA levels were significantly 
increased in SIV-infected pigtailed macaques at 84 days p.i. compared to uninfected controls 
(P = 0.003, Mann-Whitney, Figure 1). To determine whether development of SIV 
encephalitis was related to CSF1 expression levels, the 84 day p.i. SIV-infected group was 
subdivided into SIV-infected animals with (n = 8) or without SIV encephalitis (n = 5). CSF1 
mRNA expression was significantly increased in the animals with SIV encephalitis versus 
those without encephalitis (P = 0.002, Mann-Whitney, Figure 1). 
To determine whether CSF1 expression was altered during the asymptomatic phase of 
infection, CSF1 mRNA counts in basal ganglia of SIV-infected pigtails euthanized at 21 days 
p.i. were compared with uninfected and 84 day groups. The asymptomatic SIV group had 
higher CSF1 expression than uninfected controls (P = 0.09, Mann-Whitney; median = 196.5 
mRNA copies) comparable to the terminal SIV-infected animals without encephalitis 





expression suggests that CSF1 alterations develop early in the course of disease; analysis of 
larger groups is needed to confirm this finding. 
Further analysis of the Nanostring nCounter dataset revealed differential expression 
of 44 additional genes in the basal ganglia of SIV-infected pigtailed macaques sacrificed 84 
days p.i. (n =13) compared to uninfected controls (n = 10). Fold change in expression was 
calculated by dividing the median expression of the SIV 84 day p.i. mRNA counts by that of 
the uninfected controls. In cases of downregulation, the value of uninfected median counts 
divided by the SIV-infected counts was a negative number. Statistical significance was 
calculated by Mann-Whitney with a Benjamini-Hochberg adjustment (P £ 0.05).  If any gene 
had mRNA counts below the limit of detection, their values were set at the limit of detection 
for use in Mann-Whitney tests. These values were also used to identify strength of 
correlations between differentially expressed genes and CSF1 RNA levels. 29 of the 45 genes 
found to be differentially expressed with SIV were highly correlated with CSF1 mRNA 
expression levels. A subset of these genes grouped functionally is represented in Table 1; the 
complete list of genes above the limit of detection is listed in Supplemental Table 1. 
Correlation was determined using Spearman’s rank analysis with a Benjamini-Hochberg 
adjustment (P £ 0.05). CSF1 mRNA levels were significantly positively correlated with 
genes involved in receptor tyrosine kinase signaling, including STAT3. As CSF1R is the only 
known receptor of CSF1, the correlation between CSF1 RNA with RTK genes indicates that 
increased CSF1 promotes CSF1R signaling. CSF1 expression was also positively correlated 
with microglial markers. Of particular interest, CD163 and CD68 expression on microglia 
have been associated with immune activation and phagocytosis (Sasaki 2017). CSF1 mRNA 





production of leukotrienes that serves as a positive regulator of inflammation. As such, 
ALOX5AP activity has been shown to increase neuronal damage in vitro (Klergeris and 
McGeer 2003). These correlations taken together suggest a regulatory relationship between 
CSF1R signaling and regulation of microglial immune responses in SIV infection.  
Given these correlations between CSF1 and microglial immune activation, the finding 
that CSF1 mRNA expression also highly correlated with genes essential in immune 
signaling, particularly those involved in the anti-viral response such as CCL2 and Mx1, was 
also consistent with a pro-inflammatory environment in the CNS. Correlations with CSF1 
also extended to genes associated with oxidative stress including SOD2, further supporting a 
relationship between CSF1R signaling and a functional immune response in the CNS.  
 
CSF1 and IL34 mRNA expression in SIV-infected pigtailed macaque frontal cortex.  
To validate the finding of increased CSF1 expression from the Nanostring nCounter 
analyses and to expand measurements to include both CSF1R ligands in grey and white 
matter, qRT-PCR was performed to quantify CSF1 and IL34 expression using samples from 
frontal cortex (Figure 2). CSF1 expression was increased in both grey and white matter 
frontal cortex samples (Figure 2, upper row). In contrast, IL34, did not change with SIV 
infection in either grey or white matter (Figure 2 , lower row). This ligand-specific 
difference has been reported in multiple CNS inflammation models (Martinez-Muriana et al. 
2016; Gerngross and Fischer 2015) and implies that CSF1 is selectively induced during 






CSF1R expression is increased in frontal cortex white matter of SIV-infected pigtailed 
macaques. 
Given upregulation of CNS CSF1 in our SIV/macaque model of HIV CNS disease, 
we next evaluated the CSF1 receptor, CSF1R, in the CNS. To identify the cell populations 
expressing CSF1R, in situ hybridization to detect CSF1R RNA was performed on macaque 
brain sections (Figure 3). CSF1R mRNA was present in both Iba-1 positive perivascular 
macrophages and parenchymal microglia (Figure 3B, C). CSF1R-IBA1 double-positive cells 
were distributed across both grey and white matter, including perivascular and subpial 
locales, suggesting that both resident and infiltrating myeloid cells express CSF1R. Of 
particular interest, highest numbers of CSF1R-IBA1 double-positive cells were present in 
perivascular cuffs and microglial nodules.  
As upregulated CSF1R protein expression has been associated with several 
neuroinflammatory conditions, we visualized CSF1R protein using immunohistochemical 
staining. CSF1R immunostaining was markedly upregulated in white matter compared to 
uninfected controls (Figure 4A, B). This increase was most pronounced within perivascular 
cuffs composed of macrophages that are characteristic of SIV encephalitis (Figure 4B inset). 
Increased CSF1R staining was associated with a change in microglial morphology. In the 
SIV and SIV + ART groups, microglia were larger with broad processes as compared to 
uninfected animals (Figure 4B, C). CSF1R immunostaining was significantly increased in 
white matter of SIV-infected macaques compared to uninfected animals (P = 0.02, Mann-
Whitney; median %ROI positive for CSF1R in SIV = 0.87 (n= 8 animals) versus 0.50 in 
uninfected macaques (n=7 animals)). CSF1R immunostaining was also increased in grey 





Whitney; median %ROI positive for CSF1R in SIV = 0.99 versus 0.53 in uninfected 
macaques).  In previous studies, changes in the white matter have been the most predictive of 
HAND development in HIV-infected patients (Cardenas et al. 2009). This further suggests a 
role for CSF1R expression and its signaling in the pathogenesis of neurologic disease in SIV 
infection.  
Immunostaining results for CSF1R expression were confirmed by performing ELISA 
measurements on frontal cortex white matter homogenates. CSF1R protein levels were 
significantly increased in SIV-infected pigtailed macaques compared to uninfected macaques 
(P = 0.018, Mann-Whitney, Figure 5). Additionally, there was no difference in CSF1R 
protein levels between the SIV and the SIV + ART groups (P > 0.999, Mann-Whitney). 
Collectively, these data demonstrate that CNS CSF1R expression by microglia is upregulated 

















In this study based in the SIV/pigtailed macaque model of HIV CNS disease, we 
found that CSF1 expression is significantly increased in the CNS in both grey and white 
matter with SIV infection. This increase was most pronounced in SIV-infected animals that 
developed SIV encephalitis. CSF1 mRNA levels in the brain were strongly correlated with 
upregulation of immune activation and oxidative stress genes. The increase in CSF1 
expression in our pigtailed macaque model of HIV CNS disease is in contrast to the work 
done in the rhesus macaque model of HIV CNS disease where a decrease in CSF1 expression 
was observed (Gerngross and Fischer 2015).  
Interestingly, although IL34, the other ligand that binds CSF1R, is primarily 
expressed in the CNS (Zelante and Ricciardi-Castagnoli 2012), IL34 mRNA expression did 
not change with SIV infection. Similarly, a lack of a change in IL34 expression has been 
shown in other models of neurodegenerative diseases including SIV infection of rhesus 
macaques (Martinez-Muriana et al. 2016; Gerngross and Fisher 2015). Other groups have 
also noted that high concentrations of IL34 in media promotes ramified microglial 
morphology in vitro, suggesting that IL34 promotes a resting state (Muffat et al. 2016). 
Together, these findings suggest that induction of CSF1 rather than IL34 is the key driver of 
increased CSF1R signaling during neuroinflammatory processes including HIV-induced 
CNS inflammation. This is further supported by the strong correlation between CSF1 and 
receptor tyrosine kinase signaling in the SIV/pigtailed macaque model. 
Both CSF1 and IL34 have been evaluated in a SIV rhesus macaque model, but 
CSF1R has not been examined in detail. CSF1R is expressed by microglia, including 





Stanley and Chitu 2014). Like the ligand CSF1, CSF1R protein levels were significantly 
increased in the CNS of SIV-infected pigtailed macaques. Surprisingly, CSF1R expression 
by microglia also remained elevated in ART-treated SIV-infected pigtailed macaques despite 
sustained suppressive therapy. The significant increase in CSF1R expression shown by both 
CSF1R ELISA and digital image analysis of CSF1R immunostaining may represent 
sustained microglial immune activation, increased trophic demand from stressed microglia, 
or a combination of these. Together, these findings suggest that CSF1 and CSF1R may also 
remain upregulated in the CNS of HIV-infected patients treated with ART and could 
contribute to the sustained CNS inflammation suspected to underpin HAND. 
Although it has been suggested that CSF1R is an M2 marker (Ohashi et al. 2017), the 
M1/M2 polarization paradigm may not be applicable to microglia (Ransohoff 2016). As 
CSF1 expression correlates with both M1 and M2 markers, notably CD14 and CD68 
respectively, as well as genes associated with driving M1 and M2 polarization (Martinez and 
Gordon 2014), it follows that CSF1R is not representative of either M1 or M2 
immunophenotypes. This activation axis is a fluid spectrum, and it is likely that any given 
microglial cell can behave in an equally fluid manner in response to insult. It is possible that 
CSF1R signaling plays an anti-inflammatory role, in which case coordinate upregulation of 
CSF1 and its receptor, CSF1R, could represent a CNS response to mitigate the strong pro-
inflammatory response to SIV. An alternate possibility is that CSF1R signaling indirectly 
promotes the pro-inflammatory environment by increasing the survival and proliferation of 
microglia. In light of studies showing damage by removing CSF1R-expressing microglia at 
the beginning of disease progression (Jin et al. 2017) and others showing the opposite effect 





is possible that CSF1R signaling may be protective at the initiation of disease, but becomes 
damaging with persistent sustained immune stimulation. 
Evidence of a relationship between CSF1R over-expression, increased signaling 
through CSF1R, and the pathogenesis of neurodegenerative diseases such as Alzheimer’s 
Disease and amyotrophic lateral sclerosis in mouse models (Elmore et al. 2014; Dagher et al. 
2015; Martinez-Muriana et al. 2016) suggests that this CSF1R immunoregulatory role 
extends beyond HIV to chronic CNS immune activation in general. However, considering the 
strong correlations between CSF1 expression and the genes associated with the anti-viral 
response in particular, upregulation of CSF1R in SIV-infected macaques may also be linked 
to SIV replication within the CNS. Whether upregulation of CSF1R represents a direct 
immune response to virus, an enhanced demand for trophic support by damaged microglia, or 
a combination of these remains to be determined. 
Given these findings and our study results, inhibiting CSF1R signaling may prove to 
be an effective therapy for chronic inflammation in the CNS, such as that seen in HAND. 
Future studies testing the ability of CSF1 receptor blockade to deplete microglia in SIV-
infected macaques receiving suppressive ART will enable us to determine whether microglia 
depletion alters persistent immune activation present in SIV-infected macaques receiving 
ART to model HIV CNS disease.  Moreover, CSF1R blockade to target and selectively 
deplete brain macrophage populations harboring latent, replication competent HIV will be a 
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  Uninfected vs SIV mRNA Counts Correlation with 
CSF1 mRNA  
 Gene Fold Change SEM P value Spearman R P 
Val
ue 
RTK Signaling STAT1 7.9 U: 20.49 0.002 0.60 0.0
51 
 
 S: 468.6 
 STAT3 2.1 U: 24.88 0.05 0.96 0.0
02  S: 110.4 
 STAT5a 2.1 U: 7.42 0.01 0.82 0.0
05  S: 19.36 
 TYK2 1.3 U: 8.67 0.04 0.63 0.0
4  S: 20.24 
Mf/Microglia CD14 4.2 U: 10.64 0.002 0.87 0.0
03  S: 82.75 
 CD16* 6.9 U: 0.70 *0.002 0.71 0.0
16 
 
 S: 13.49 
 CD68* 9.0 U: 4.05 *0.009 0.80 0.0
06 
 
 S: 82.22 
 CD163 13.8 U: 8.80 0.004 0.72 0.0
1  S: 316 
 ALOX5AP 3.1 U: 11.78 0.009 0.75 0.0
1  S: 85.05 
Immune Activation CCL2 50.6 U: 2.78 0.002 0.84 0.0
04  S: 288.3 
 IRF1 17.7 U: 3.33 0.002 0.92 0.0
2  S: 137.3 
 IRF3 1.2 U: 41.34 0.04 0.72 0.0
2  S: 47.8 
 MX1 48.9 U: 42.88 0.002 0.74 0.0
1  S: 1957 
Oxidative Stress SOD2 7.2 U: 112.2 0.009 0.91 0.0
02  S: 5744 
 GPX1 2.2 U: 104.4 0.006 0.74 0.0
05  S: 191.3 
 GSTZ1 1.4 U: 12.59 0.054 0.82 0.0









Table 2-1. With SIV infection, a subset of genes expressed in the brain was significantly 
correlated with CSF1 mRNA counts. Uninfected versus SIV P values were calculated 
using normalized mRNA counts (Mann-Whitney). Correlations were calculated only using 
SIV mRNA counts. All P values were adjusted using Benjamini-Hochberg correction. 
*Values below the limit of detection were set at the limit of detection to calculate the 








Figure 2-1. Nanostring analysis of CSF1 mRNA expression in SIV-infected pigtailed 
macaques. CSF1 mRNA counts in basal ganglia of SIV-infected macaques were 
significantly increased versus uninfected animals. CSF mRNA expression was also 
significantly higher in animals with SIV encephalitis compared to SIV-infected animals 












Figure 2-2. CSF1 mRNA significantly increased with SIV infection. CSF1 mRNA 
expression measured by qRT-PCR significantly increased in SIV-infected macaques (frontal 
cortex) compared to uninfected animals in both grey and white matter (top row). In contrast, 
there was no significant difference in IL34 expression in either grey or white matter. (No 









Figure 2-3. Constitutive and induced CSF1R expression was restricted to microglia. (A) 
CSF1R ISH bright-field shows positive staining (red) in both parenchymal microglia 
(arrows) and perivascular macrophages (arrowheads). (B) CSF1R RNA (red) co-localizes 
with Iba1-positive microglia (brown).  Double stained cells are denoted by arrowheads. (C) 
Overlaid CSF1R ISH fluorescence image of (B) confirmed localization of CSF1R RNA 

















Figure 2-4. Elevated CSF1R protein in both untreated and ART-treated SIV-infected 
pigtailed macaques. (A) Constitutive CSF1R staining in the frontal cortex of an uninfected 
untreated macaque. Both perivascular macrophages and parenchymal microglia were 
positively immunostained for CSF1R (red). (B) A marked increase in CSF1R 
immunostaining developed with SIV infection. Inset: Perivascular cuff of macrophages with 
high CSF1R expression. (C) CSF1R immunostaining remained elevated in microglia in SIV-










Figure 2-5. Elevated CNS CSF1R Expression in SIV and SIV+ART. Measurements of 
CSF1R protein levels in frontal cortex by ELISA showed a significant increase in CSF1R 
concentration in the SIV-infected group (Mann-Whitney). With suppressive ART, CSF1R 









Supplemental Table 2-1 
 











n p (BH) 
CSF1 3.16 146.2 +/- 15.29 140.5 0.01 1 N/A* 
  405.8 +/- 56.24 444    
AADAT -1.33 161.9 +/- 6.31 168.5 0.009 -0.1458 0.662127
907 
  128 +/- 6.06 127    
AGER 1.26 25.3 +/- 3.56 21.5 0.23 N/A N/A 
  28.85 +/- 2.39 27    
ALOX5AP 3.06 148 +/- 11.78 134 0.002 0.75 0.011117
647 
  477.9 +/- 85.05 410    
APP -1.27 11694 +/- 
350.2 
11925 0.002 -0.3846 0.237770
27 
  9110 +/- 450.3 9360    
ARG2 -1.24 216.7 +/- 20 233 0.45 N/A N/A 
  189.4 +/- 14.69 188    
CAMK2A -1.11 3200 +/- 708.7 2468 0.29 N/A N/A 
  2009 +/- 304.2 2220    
CAMK2B -1.18 1510 +/- 219.2 1354 0.43 N/A N/A 
  1124 +/- 182.4 1146    
CAMK2D -1.09 742 +/- 171.9 568.5 0.68 N/A N/A 
  519.2 +/- 72.61 522    
CAMK2G -1.70 1037 +/- 140.4 986 0.04 0.4066 0.211875 
  655 +/- 65.12 579    
CAT 1.47 246.8 +/- 24.92 237 0.2 N/A N/A 
  335.3 +/- 36.6 348    
CCBL1 1.07 204 +/- 9.6 199 0.97 N/A N/A 
  199.5 +/- 15.54 213    
CCBL2 1.03 850.3 +/- 42.66 861 0.43 N/A N/A 
  944.5 +/- 62.28 888    
CCL2 50.55 21.9 +/- 2.78 20 0.002 0.8352 0.0045 
  1119 +/- 288.3 1011    
CCR1 1.88 85.8 +/- 9.221 82.5 0.0053 0.4835 0.132409
091 
  165.5 +/- 17.46 155    
CCS -1.17 152.7 +/-6.57 151 0.15 N/A N/A 





CD14 4.24 116.8 +/- 10.64 117 0.002 0.8681 0.003375 
  477.7 +/- 82.75 496    
CD16 6.90 11.31 +/- 0.70 10 0.002 0.7088 0.016125 
  69.15 +/- 13.49 69    
CD163 9.01 78.5 +/- 8.80 79.5 0.004 0.7198 0.014282
609 
  1207+/- 316 1095    
CD68 13.77 50.6 +/- 4.05 49.5 0.01 0.8006 0.006230
769 
  420.8 +/- 82.22 473    
CHRNA7 -1.01 88.1 +/- 8.34 83 0.8 N/A N/A 
  82 +/- 3.40 82    
CHRNB2 -1.48 501.8 +/- 49.07 513.5 0.025 -0.8088 0.00525 
  313.2 +/- 40.62 347    
CNOT8 -1.31 563.8 +/- 18.47 586 0.002 -0.3077 0.344587
5 
  448.8 +/- 13.03 447    
CNTF 1.35 61.6 +/- 6.07 54 0.45 N/A N/A 
  71.54 +/- 7.25 73    
COMT 1.14 302.3 +/- 17.16 316 0.07 N/A N/A 
  434.2 +/- 41.58 359    
CX3CL1 -1.26 2168 +/- 207.2 2279 0.6 N/A N/A 
  1992 +/- 171.9 1803    
CX3CR1 -1.10 614.5 +/- 60.37 543 0.29 N/A N/A 
  495.5 +/- 114.4 492    
CXCL12 1.53 255.7 +/- 20.39 241 0.02 0.1209 0.711818
182 
  388.8 +/- 31.97 369    
CXCR4 1.92 41.4 +/- 6.39 38.5 0.054 N/A N/A 
  68.69 +/- 8.12 74    
CYBA 1.97 102.4 +/- 12.91 108 0.006 0.3571 0.267230
769 
  219.8 +/- 21.94 213    
DGCR8 1.07 234.6 +/- 9.46 232 0.68 N/A N/A 
  243.7 +/- 9.57 248    
DICER -1.16 421 +/- 15.92 427.5 0.07 N/A N/A 
  366 +/- 15.39 368    
DLG4 -1.37 3834 +/- 433.2 4162 0.33 N/A N/A 
  2983 +/- 427.2 3036    
DROSHA -1.15 775.3 +/- 40.14 785 0.16 N/A N/A 





EDN1 1.74 72.1 +/- 7.25 78 0.026 0.2198 0.503892
857 
  151 +/- 19.85 136    
EIF2C1 -1.11 560.2 +/- 17.34 563.5 0.14 N/A N/A 
  492.5 +/- 27.54 507    
EIF2C2 -1.02 738.3 +/- 32.76 758 0.84 N/A N/A 
  737.1 +/- 17.97 744    
ENO2 -1.28 4701 +/- 227.9 4701 0.04 -0.6703 0.0245 
  3627 +/- 269.1 3669    
GFAP 3.00 2109 +/- 5414 17993 0.07 N/A N/A 
  54809 +/- 9645 53960    
GLRX 1.63 335.1 +/- 15.68 342.5 0.14 N/A N/A 
  546.4 +/- 70.36 558    
GLS -1.50 2058 +/- 203.1 1848 0.005 -0.7912 0.006428
571 
  1234 +/- 131.8 1235    
GLS2 -1.14 110.8 +/- 12.42 107.5 0.7 N/A N/A 
  97.08 +/- 11.41 94    
GLUD1 -1.13 2917 +/- 155.4 2865 0.2 N/A N/A 
  2574 +/- 120.5 2532    
GLUL 1.12 6412 +/- 520.3 6520 0.24 N/A N/A 
  7820 +/- 640.6 7328    
GOT1 -1.32 886.1 +/- 32.31 865.5 0.002 -0.8297 0.0045 
  659.4 +/- 35.14 657    
GOT2 -1.20 1026 +/-51.39 1023 0.015 0.03297 0.9205 
  840 +/- 30.62 849    
GPX1 2.19 751.7 +/- 104.4 840 0.006 0.7363 0.0126 
  1691 +/- 191.3 1842    
GPX3 1.22 349.7 +/- 79 251 0.89 N/A N/A 
  414.3 +/- 103 305    
GPX4 -1.12 1445 +/- 43.67 1479 0.22 N/A N/A 
  1328 +/- 58.92 1338    
GPX7 1.52 61.2 +/- 2.95 58.5 0.01 0.2198 0.503892
857 
  86.46 +/- 6.14 89    
GSR 1.17 450.5 +/- 13.73 428 0.15 N/A N/A 
  500.2 +/- 21.34 502    
GSS 1.07 199.2 +/- 19.64 176 0.92 N/A N/A 
  2009 +/- 16.59 188    





  182.8 +/- 12.16 180    
HAAO -1.04 80.1 +/- 7.11 78 0.68 N/A N/A 
  74 +/- 7.50 75    
IFNaR 1.02 599.1 +/- 21.41 602 0.68 N/A N/A 
  605.8 +/- 18.25 616    
IL18 1.40 230 +/- 22.52 215.5 0.07 N/A N/A 
  352.2 +/- 49.95 301    
IL18BP 4.00 106.3 +/- 4.83 104.5 0.01 0.7857 0.0066 
  383 +/- 66.58 418    
IRF1 17.74 41 +/- 3.33 42 0.002 0.9231 0.0015 
  627.8 +/- 137.3 745    
IRF3 1.22 639.9 +/- 41.34 643 0.04 0.7235 0.014282
609 
  816.3 +/- 47.8 785    
ITGAM 1.08 109.6 +/- 10.07 108.5 0.9999 N/A N/A 
  106.2 +/- 10.72 117    
MAOA 1.10 451 +/- 46.36 436 0.64 N/A N/A 
  629.5 +/- 120.3 481    
MAOB 1.28 1503 +/- 175.9 1537 0.14 N/A N/A 
  2285 +/- 275.7 1973    
MAP2 -1.10 5855 +/- 356.7 5823 0.13 N/A N/A 
  4775 +/- 430.1 5275    
MBP -1.41 28939 +/- 6191 28731 0.33 N/A N/A 
  21579 +/- 4218 20428    
MPV17 1.12 206.7 +/- 7.21 205 0.14 N/A N/A 
  229.4 +/- 9.37 230    
Mx1 48.92 266.4 +/- 42.88 221 0.002 0.7418 0.012078
947 
  9663 +/- 1957 10812    
OGT 1.18 1576 +/- 103.1 1529 0.33 N/A N/A 
  1817 +/- 176.7 1802    
PCNA 1.27 377.5 +/- 13.94 378 0.15 N/A N/A 
  503.5 +/- 39.56 481    
PDGFA -1.32 272.2 +/- 31.62 314 0.56 N/A N/A 
  305.9 +/- 38.49 238    
PDGFB 1.13 65.4 +/- 3.77 63 0.24 N/A N/A 
  77.85 +/- 6.37 71    
PDGFC 1.19 91.1 +/- 9.39 79.5 0.76 N/A N/A 





PDLIM1 1.32 37.6 +/- 3.37 37 0.08 N/A N/A 
  85.69 +/- 15.57 49    
PECAM1 2.50 264.9 +/- 12.12 268 0.002 0.7802 0.007031
25 
  626.8 +/- 69.23 670    
PRDX1 1.70 1365 +/- 149.5 1240 0.055 N/A N/A 
  2079 +/- 221.2 2111    
PRDX2 -1.09 1043 +/- 38.11 1014 0.33 N/A N/A 
  920.2 +/- 56.01 927    
PRDX3 1.12 1918 +/- 116.5 1848 0.68 N/A N/A 
  1976 +/- 90.82 2069    
PRDX4 1.35 178.9 +/- 9.96 174.5 0.3 N/A N/A 
  218 +/- 18.66 236    
PRDX6 1.21 2152 +/- 156.8 2128 0.14 N/A N/A 
  2565 +/- 159.6 2571    
PRNP -1.09 4450 +/- 252.4 4387 0.3 N/A N/A 
  3976 +/- 251.7 3920    
PTGDS -1.17 5493 +/- 904.4 5360 0.8 N/A N/A 
  4766 +/- 467.3 4571    
PTGES2 1.03 299.6 +/- 22.46 283 0.97 N/A N/A 
  280.3 +/- 22.08 297    
RBFOX3 -1.47 1816 +/- 269 2084 0.15 N/A N/A 
  1210 +/- 190.1 1419    
SAMHD1 3.67 167 +/- 11.71 166 0.002 0.8571 0.0036 
  566.8 +/- 82.64 609    
SLC1A2 -1.64 17290 +/- 1854 17499 0.1 N/A N/A 
  11382 +/- 1790 10690    
SLC1A3 1.19 10185 +/- 
395.4 
10149 0.1 N/A N/A 
  13630 +/- 1278 12077    
SLC2A1 1.16 91.1 +/- 5.02 95 0.054 N/A N/A 
  108.7 +/- 4.29 110    
SNAP25 -1.34 16027 +/- 1647 16054 0.2 N/A N/A 
  11669 +/- 1280 12023    
SOD1 1.07 5444 +/- 122.9 5463 0.5 N/A N/A 
  5761 +/- 261.9 5848    
SOD2 7.17 3608 +/- 112.2 3667 0.01 0.9066 0.0015 
  23509 +/- 5744 26304    






  605.6 +/- 138.6 558    
SRXN1 1.05 383.1 +/- 43.17 370 0.2 N/A N/A 
  469.8 +/- 49.11 388    
STAT1 7.90 427.7 +/- 20.49 429.5 0.002 0.5989 0.051 
  3031 +/- 468.6 3401    
STAT2 5.13 152.8 +/- 8.89 146.5 0.004 0.7473 0.0115 
  578.8 +/- 91.36 752    
STAT3 2.14 427.4 +/- 24.88 421 0.049 0.956 0.0015 
  851.2 +/- 110.4 901    
STAT5A 2.09 110.7 +/- 7.42 111 0.01 0.8187 0.00495 
  205.8 +/- 19.36 232    
STAT5B 1.00 343.2 +/- 12.28 346.5 0.9 N/A N/A 
  347.1 +/- 14.93 346    
STK25 -1.15 1039 +/- 78.52 1149 0.63 N/A N/A 
  947.9 +/- 82.13 1000    
SYP -1.50 3478 +/- 604.4 2960 0.049 -0.6758 0.023711
538 
  2086 +/- 173.4 1969    
TARBP2 1.04 121 +/- 7.81 119 0.97 N/A N/A 
  120.6 +/- 7.58 124    
TGFA 1.08 66.1 +/- 8.37 55.5 0.68 N/A N/A 
  61.54 +/- 6.69 60    
TGFB1 -1.19 285.4 +/- 19.01 265 0.04 0.4066 0.211875 
  424.3 +/- 49.36 384    
TGFB2 1.98 417.6 +/- 38.64 395 0.015 0.8407 0.0045 
  796.8 +/- 97.44 783    
TGFB3 1.23 242.8 +/- 12.33 239 0.41 N/A N/A 
  297.8 +/- 31.39 294    
TJP1 -1.10 1683 +/- 105.5 1813 0.52 N/A N/A 
  1611 +/- 71.37 1644    
TJP2 1.16 256.5 +/- 33.77 225.5 0.6 N/A N/A 
  311.5 +/- 37.53 262    
TLR1 1.47 111.5 +/- 9.42 104 0.005 0.4842 0.132409
091 
  188.2 +/- 17.41 153    
TLR3 2.87 78.5 +/- 9.86 86 0.002 0.7033 0.01674 
  201.5 +/- 26.05 195    
TLR4 2.20 157.2 +/- 24.79 143.5 0.002 0.533 0.093193
548 





TLR5 1.49 32.6 +/- 4.89 27.5 0.18 N/A N/A 
  42.38 +/- 3.74 41    
TLR6 1.41 101.8 +/- 7.26 100.5 0.015 0.3681 0.256618
421 
  147.5 +/- 11.62 142    
TLR7 1.36 68.9 +/- 6.817 60.5 0.45 N/A N/A 
  91.38 +/- 14.73 82    
TNFRSF10A 2.10 32.6 +/- 4.72 29.5 0.002 0.8077 0.00525 
  71.54 +/- 9.98 62    
TNRC6A -1.03 577.1 +/- 19.88 563.5 0.77 N/A N/A 
  558.1 +/- 21.97 548    
TP53 2.10 50 +/- 2.91 50.5 0.01 0.7198 0.014282
609 
  94.62 +/- 10.32 106    
TRIM32 -1.08 287 +/- 10.67 294 0.6 N/A N/A 
  273.2 +/- 19.85 272    
TSPAN7 -1.39 14302 +/- 
942.4 
14992 0.18 N/A N/A 
  10986 +/- 1221 10810    
TUBB3 -1.39 1954 +/- 265 1942 0.24 N/A N/A 
  1464 +/- 133.6 1397    
TXN 1.04 4156 +/- 258.6 3959 0.88 N/A N/A 
  4235 +/- 208 4101    
TXNRD1 1.16 971.1 +/- 39.36 984 0.02 0.6044 0.049655
172 
  1184 +/- 49.63 1140    
TXNRD2 -1.19 237 +/- 16.46 245 0.3 N/A N/A 
  210.8 +/- 13.66 206    
TYK2 1.26 244.6 +/- 8.67 238 0.04 0.6319 0.037928
571 
  309.5 +/- 20.24 301    
VEGFA 1.07 236.6 +/- 12.71 229.5 0.81 N/A N/A 
  241.2 +/- 16.63 245    
VEGFB -1.19 351.4 +/- 20.78 360.5 0.5 N/A N/A 
  327.7 +/- 30.17 302    
 
Supplemental Table 2-1. Genes above the limit of detection that were significantly 
changed after 84 days of SIV infection in the basal ganglia and their correlation scores 















Differential Regulation of TREM2 and CSF1R in CNS Macrophages in an 


























HIV-associated neuroinflammation is primarily driven by CNS macrophages 
including microglia. Regulation of these immune responses, however, remains to be 
characterized in detail. Using the SIV/macaque model of HIV, we evaluated CNS expression 
of Triggering Receptor Expressed on Myeloid cells 2 (TREM2) which is constitutively 
expressed by microglia and contributes to cell survival, proliferation, and differentiation. 
Loss-of-function mutations in TREM2 are recognized risk factors for neurodegenerative 
diseases including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and Nasu-
Hakola disease (NHD); recent reports have also indicated a role for TREM2 in HIV-
associated neuroinflammation. Using in situ hybridization (ISH) and qRT-PCR, TREM2 
mRNA levels were found to be significantly elevated in frontal cortex of macaques with SIV 
encephalitis compared to uninfected controls (P = 0.02). TREM2 protein levels were also 
elevated as measured by ELISA of frontal cortex tissue homogenates in these animals. 
Previously, we characterized the expression of CSF1R (colony stimulating factor 1 receptor) 
in this model; the TREM2 and CSF1R promoters both contain a PU.1 binding site. While 
TREM2 and CSF1R mRNA levels in frontal cortex were highly correlated (Spearman R = 
0.79, P < 0.001), protein levels were not well correlated. In SIV-infected macaques released 
from ART to study viral rebound, neither TREM2 nor CSF1R mRNA increased with 
rebound viremia. However, CSF1R protein levels remained significantly elevated unlike 
TREM2 (P = 0.02). This differential expression suggests that TREM2 and CSF1R play 








Triggering Receptor Expressed on Myeloid cells 2 (TREM2) is an immunoglobulin-
like receptor expressed on cells of the myeloid lineage. Within the brain, TREM2 is primarily 
expressed by parenchymal microglia and perivascular macrophages. TREM2 signaling 
promotes survival and proliferation of these cells. It has also been suggested that TREM2 
plays a role in immune regulation and activation (Konishi and Kiyama 2018).  
TREM2 loss-of-function mutations in humans are associated with several 
neurodegenerative diseases. In particular, loss-of-function mutations in humans have been 
linked to the development of Alzheimer’s disease (AD) (Jonsson et al. 2013; Guerreiro et al. 
2013), Nasu-Hakola disease (NHD) (Dardiotis et al. 2017), and frontotemporal dementia 
(FTD) (Thelen et al. 2014). This highlights the clinical significance of TREM2 in 
neurodegeneration.  
The potential role of TREM2 in the development of AD was further characterized in 
murine model systems, which ultimately showed that increased TREM2 signaling from 
baseline can be protective at the onset of disease but then detrimental at later stages of the 
disease (Yeh et al. 2017). It has also been shown in mice that TREM2-expressing microglia 
surround amyloid beta plaques, further suggesting a sequestering and protective role of these 
cells (Wang et al. 2016). This shows that increased TREM2 activation is beneficial and 
protective at the onset of neurodegenerative disease. However, long-term activation of 
TREM2 can also contribute to neurodegenerative diseases, suggesting that the role of 
TREM2 signaling in neurodegeneration is time dependent (Jay et al. 2015). Therefore, it is 
important to maintain a homeostatic balance of TREM2 signaling to maintain CNS health. 





the pathogenesis amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) in a mouse 
model (Krasemann et al. 2017).  
Much like TREM2, increased expression of colony stimulating factor 1 receptor 
(CSF1R) has been linked to many of these same neurodegenerative diseases including AD 
(Akiyama et al. 1994). TREM2 and CSF1R are both highly expressed within the CNS by 
microglia (Chitu et al. 2016). Additionally, TREM2 and CSF1R share the transcription factor 
PU.1 (Satoh et al. 2014). We have previously shown that CSF1R is upregulated within the 
CNS of SIV-infected pigtailed macaques, demonstrating a role for CSF1R in promoting HIV 
CNS disease (Knight et al. 2018). Similar findings were reported for HIV (Irons et al. 2019). 
Recent reports also described altered TREM2 expression in HIV-infected individuals with 
HIV-associated neurocognitive disorder (HAND) (Fields et al. 2018; Gisslén et al. 2018).  
As HAND is thought to be due to sustained CNS inflammation even with suppressive 
anti-retroviral therapy, microglia likely play an essential role in its pathogenesis (Saylor et al. 
2016). In particular, we hypothesized that chronic activation of TREM2 and CSF1R 
signaling contributes to the pathogenesis of HIV CNS disease. It has been previously 
established that TREM2 signaling is linked to CSF1R-related downstream affects in 
macrophages (Otero et al. 2009). Other studies have further shown a coordinated effect of 
TREM2 and CSF1R signaling via the accessory protein DNAX activating protein 12 
(DAP12) resulting in sensory nerve damage due to microglial proinflammatory activity 
(Guan et al. 2016; Kobayashi et al. 2016). However, it is yet to be established whether 
TREM2 and CSF1R signaling are directly linked and causative in HIV CNS disease or other 





be associated with SIV CNS disease in our SIV/pigtailed macaque model in parallel with 









Samples from juvenile male pigtailed macaques (Macaca nemestrina) were used for 
these studies dependent on sample availability. All animals were specific pathogen free for 
Macacine herpesvirus 1 (B virus), simian immunodeficiency virus (SIV), simian T-cell 
leukemia virus (STLV-1), and simian retrovirus (SRV).  At necropsy, all animals were 
perfused with phosphate buffered saline. When collected, brains were sectioned coronally 
and either immersion fixed in 10% neutral buffered formalin (NBF) or Streck tissue fixative 
(STF), or snap-frozen in liquid nitrogen. All flash-frozen samples were stored at -80°C from 
the time of initial collection at necropsy until use.  
Samples from five groups of juvenile male pigtailed macaques (Macaca nemestrina) 
were evaluated as available: 1) uninfected controls that were mock inoculated with Lactated 
Ringers Solution (LRS) (n = 9), 2) SIV-infected animals that were intravenously inoculated 
with both the immunosuppressive swarm SIV/DeltaB670 and the molecular clone SIV/17E-
Fr and euthanized 42 days post infection (dpi; n = 6), 3) SIV-infected animals that were 
intravenously inoculated with SIV/DeltaB670 and SIV/17E-Fr and euthanized 84 dpi unless 
the animal developed AIDS-defining criteria, in which case the animal was euthanized at that 
time (n = 9), 4) SIV-infected animals treated with a suppressive ART regimen (SIV + ART) 
beginning 12 days post-SIV inoculation (n = 7) (Beck SE et al. 2015; Beck SE et al. 2017; 
Beck SE et al. 2015), and 5) SIV-infected animals treated with ART and then released from 
their ART-regimen after 120 days of suppression of SIV (n = 10) (Supplemental Table 1). 
SIV + ART animals were treated with a combination injectable regimen of 2.5 mg/kg 





(Gilead, Foster City, CA) administered daily subcutaneously. Four of the seven SIV + ART 
animals also received an oral dose of 20 mg of maraviroc (ViiV Healthcare, US, Raleigh, 
NC) daily. SIV + ART animals were suppressed in both plasma and CSF by 56 days p.i. and 
were euthanized 180 days p.i. Animals that were released from treatment were given the 
same ART regimen as listed above. Six of the 12 animals released from treatment received 
maraviroc. Release animals were euthanized at a viral set point in plasma, defined as three 
consecutive time points with viral loads within one log. Maraviroc did not have an effect on 
time to suppression, time to rebound, or any macrophage/microglial markers and thus were 
included to increase group size (Knight et al. 2018). All animal studies were approved by the 
Johns Hopkins Animal Care and Use Committee. 
 
In situ hybridization to detect TREM2 RNA  
In situ hybridization (ISH) was performed on 5µm thick sections of frontal cortex 
after immersion fixation in 10% NBF followed by paraffin embedding. Staining was 
performed using the Leica Bond RX automated system (Leica Biosystems, Richmond, IL). 
The TREM2 probe (cat. 432238, Advanced Cell Diagnostics, Newark, NJ) was used with the 
Leica RNAScope 2.5 LS Assay-RED kit and a hematoxylin counterstain (Leica Biosystems, 
Richmond, IL). Slides were treated in protease (Advanced Cell Diagnostics, Newark, NJ) for 
15 minutes and probes hybridized to RNA for 1 minute.  
 
TREM2 ISH and IBA1 IHC dual staining 
TREM2 ISH was combined with IBA1 immunostaining performed on frontal cortex 





first heat-induced epitope retrieval was conducted by heating slides to 95°C in EDTA-based 
ER2 buffer for 15 minutes (Leica Biosystems, Richmond, IL). Slides were then stained with 
anti-IBA1 antibody (cat. 01919741, Wako, Richmond, VA) at a dilution of 1:500. IHC was 
performed using the Bond RX automated system (Leica Biosystems, Richmond, IL). A 
second heat-induced epitope retrieval was conducted by heating slides to 95°C for 20 
minutes in sodium citrate-based ER1 buffer (Leica Biosystems, Richmond, IL). Positive 
immunostaining was visualized using DAB, and slides were counterstained with 
hematoxylin. 
 
PU.1 Immunohistochemistry and image analysis 
 Streck tissue fixative-fixed frontal cortex sections of uninfected, 84d SIV-infected, 
SIV + ART, and release pigtailed macaques were stained with anti-PU.1 antibody (cat. 
PA517505, Invitrogen, Carlsbad, CA) at a dilution of 1:100. Heat-induced epitope retrieval 
was conducted by heating slides to 95°C for 20 minutes in sodium citrate-based ER1 buffer 
(Leica Biosystems, Richmond, IL). Nikon Elements software (Nikon, Melville, NY) was 
utilized for image acquisition and positive object count analysis. Images were composed of 
36 contiguous 200X fields covering cortical grey and white matter. A threshold was set to 
determine positive staining to perform object count analysis that counted PU.1-
immunopositive cells.  
 
Quantitative RT-PCR 
RNA was isolated from flash-frozen white matter frontal cortex or parietal cortex as 





kit (Applied Biosystems, Carlsbad, CA) was used for both reverse transcriptase (RT) and no 
reverse transcriptase (NRT) reactions. RT reactions were run in duplicate. One microgram of 
RNA was added to each reaction. RT step was performed using the PTC 200 (MJ Research, 
Port Republic, NJ) as previously described (Knight et al. 2018). Four microliters of cDNA 
from these reactions were then added to qPCR reactions. Each reaction contained the 
TaqMan ® Universal Master Mix II or the Gene Expression Master Mix (Applied 
Biosystems, Carlsbad, CA) with one of two multiplexed probe mixes. The TREM2 probe 
(cat. Hs00219132_m1, ThermoFisher Scientific, Waltham, MA) was multiplexed with the 
18S probe, while the CSF1R probe (cat. Hs00911250_m1, ThermoFisher Scientific) was 
multiplexed with the CSF1 probe (cat. Rh02621778_m1, ThermoFisher Scientific) probe. As 
TREM2 and CSF1R probes were not available for the macaque genes, human probes were 
used. There is significant homology between the human and macaque TREM2 and CSF1R 
genes (96% and 92% homology respectively). Both multiplexed reactions were run in 
parallel, and each sample was run in duplicate. qPCR was performed using the C1000 Touch 
thermal cycler and the CFX96 Real-Time PCR Detection System (Bio Rad, Hercules, CA) as 
previously described (Knight et al. 2018). All RNA counts were normalized to 18S ribosomal 
RNA counts and reported as DDCt (cycle threshold). 
 
ELISAs 
TREM2 and CSF1R ELISAs were performed using protein homogenates from frontal 
cortex sections. A total of 34 animals were included based on availability of samples. 4 mm 
biopsy punches were taken from white matter and placed in RIPA cell lysis buffer (Cell 





tissue. Samples were then sonicated. The protein concentration of each sample was measured 
using either Qubit or BCA (ThermoFisher, Waltham, MA) and validated visually using 
CriterionTM TGX Stain-Free 10% protein separation gels. The gel was imaged using the Gel 
Doc EZ-Imager (Bio-Rad, Hercules, CA). The Biomatik (Cambridge, Ontario, CA) human 
MCSFR (cat. EKU09066) and human TREM2 (cat. EKU07882) kits were used according to 
the manufacturer’s protocol. 30 ug of protein were added to the pre-coated wells in duplicate 
and positive immunoreactivity was read at 450 nm using a TMB solution. Results from SIV 
+ ART for CSF1R protein levels were previously published (Knight et al. 2018) and included 
in this study to determine differences between suppression and release. 
 
Statistical Analysis 
All statistical analysis was performed using Prism 7 or 8 GraphPad Software 
(GraphPad Software, La Jolla, CA). Non-parametric analyses included Mann-Whitney tests 
and Kruskal-Wallis tests with Dunn’s multiple comparisons. Significance was determined at 








TREM2 mRNA expression in SIV-infected pigtailed macaque frontal cortex. 
 TREM2 is constitutively expressed on cells of the myeloid lineage, specifically 
perivascular macrophages and parenchymal microglia within the CNS (Schmid et al. 2002). 
Upregulation of TREM2 has been reported in several models of CNS inflammation and 
neurodegenerative diseases (Yeh et al. 2017). To confirm this cell-specific expression pattern 
of TREM2 in the SIV/pigtailed macaque model of HIV CNS disease, in situ hybridization 
(ISH) was performed on sections of macaque frontal cortex. In uninfected pigtail macaque 
frontal cortex, low-level constitutive TREM2 positive staining could be observed in 
parenchymal microglia (Figure 1A, inset). TREM2 mRNA expression was markedly 
increased 42 days post-SIV infection. Increased TREM2 positive staining could be seen in 
both parenchymal microglia and in perivascular macrophages (Figure 1B). Localization of 
TREM2 RNA to CNS macrophages was confirmed by dual TREM2 ISH and IBA1 IHC 
staining (Supplemental Figure 1).    
 In SIV-infected macaques with encephalitis, TREM2 positive staining was also 
localized to both perivascular macrophages (Figure 1C) and parenchymal microglia (Figure 
1D). This pattern of TREM2 staining is consistent with that reported in human brain (Yeh et 
al. 2017). These findings were confirmed by qRT-PCR (Figure 2A). TREM2 mRNA 
expression increased, but not significantly (P = 0.1), at 42 days post-SIV infection in the 
frontal cortex compared to uninfected controls. At 84 days post infection, the increase in 
TREM2 mRNA was significant (P = 0.02). TREM2 mRNA returned to baseline with 
suppressive ART treatment (uninfected v SIV + ART P > 0.999). This same trend was seen 





are both controlled, at least in part, by the transcription factor PU.1 (Satoh et al. 2014), we 
determined whether or not TREM2 and CSF1R mRNA expression were correlated in this 
model. With SIV infection, TREM2 mRNA expression was highly correlated with both 
CSF1R expression (Figure 2C, Spearman R = 0.79, P = 0.0008), and the CSF1R ligand, 
CSF1 (Figure 2D, Spearman R = 0.84, P = 0.0002). These results suggest coordinated 
increase in TREM2, CSF1R, and CSF1 transcripts in the frontal cortex in response to SIV 
infection.  
 To validate these findings, we used immunohistochemistry and quantitative image 
analysis to characterize PU.1, the transcription factor common to both TREM2 and CSF1R. 
PU.1 protein significantly increased after 84 days of SIV infection in frontal cortex compared 
to uninfected controls (Figure 3 uninfected vs 84d SIV, P = 0.03). With ART suppression, 
PU.1 returned to baseline levels (Figure 3 uninfected vs SIV + ART, P > 0.999). This pattern 
closely parallels both TREM2 and CSF1R mRNA level alterations that develop with SIV 
infection, which is consistent with a regulatory role for PU.1. 
 
TREM2 and CSF1R protein levels differ despite mRNA similarities 
 Given the mRNA findings described above, we hypothesized that TREM2 protein 
levels would reflect what we previously described with CSF1R protein levels in our 
SIV/macaque model (Knight et al. 2018). To explore this possibility, we measured TREM2 
protein in frontal cortex homogenates by ELISA in samples from uninfected controls, 
untreated SIV infected pigtailed macaques euthanized 42 days and 84 days post-infection, 
and fully suppressed ART treated SIV-infected macaques. While we did not see a significant 





wide range of TREM2 protein concentrations present in the uninfected frontal cortices 
limited the statistical power of these comparisons (Figure 4A). Although not significant (P = 
0.55), levels of TREM2 protein in SIV-infected pigtailed macaques with encephalitis were 
moderately increased. Additionally, TREM2 protein levels returned to baseline with 
suppressive ART compared to levels seen in the 84-day post-infection group (Uninfected vs 
SIV + ART P > 0.999; 84d SIV vs SIV + ART P = 0.2).  
 These findings of TREM2 protein in the brain returning to baseline with suppressive 
ART contrast sharply with CSF1R protein levels in these same animals; CSF1R protein 
levels remained elevated in fully suppressed animals (Knight et al. 2018). TREM2 protein 
and CSF1R protein levels were not strongly correlated despite the observed significant 
correlation in mRNA expression (Figure 4B, Spearman R = 0.4, P = 0.03).  
 
TREM2 and CSF1R expression upon release from suppressive ART therapy. 
 To explore the potential differential roles of TREM2 and CSF1R in HIV CNS disease 
during viral rebound after treatment interruption, we measured both mRNA and protein 
expression in SIV-infected pigtailed macaques that were released from suppressive ART 
after approximately 120 days of suppression (titled ‘release group’). TREM2 and CSF1R 
mRNA expression measured by qRT-PCR in this release group was equivalent to uninfected 
controls (Figure 5A, B, uninfected v TREM2 and CSF1R P = 0.9). The number of cells 
expressing PU.1 protein was also not significantly different during the early phases of viral 






TREM2 and CSF1R protein levels were also measured in frontal cortex of the release 
group. In this group, TREM2 protein levels were not significantly higher than those of SIV + 
ART animals (Figure 6A; P = 0.86) in agreement with the mRNA expression levels. CSF1R 
protein expression, on the other hand, was higher than SIV + ART animals upon release from 
ART (Figure 6B; P = 0.14). Again, the protein levels of CSF1R diverged from its mRNA 
expression. The median fold increase from uninfected baseline of CSF1R, however, was 








 In these studies, we tracked SIV-induced alterations in both TREM2 mRNA and 
protein expression in the brain using the SIV/pigtailed macaque model of HIV-induced 
neurologic disease (Beck et al. 2015; Laast et al. 2011). As reported in humans, TREM2 was 
expressed constitutively at low levels by macrophages within the macaque brain including 
both perivascular macrophages and parenchymal microglia (Yeh et al. 2017).  TREM2 
mRNA expression significantly increased with SIV infection as shown by both in situ 
hybridization and qRT-PCR measurements. TREM2 protein levels were moderately higher in 
the frontal cortex with SIV infection; this increase was not significant, however, when 
compared to the wide range of TREM2 levels seen in uninfected control animals.  The reason 
for the variation in range of TREM2 protein in uninfected specific pathogen-free macaques is 
not known but may reflect unidentified subclinical infections or systemic immune responses 
conveyed across the blood-brain barrier. It has been reported that common, short-lived 
gastroenteritis can affect the mucosal barrier of the gut, resulting in the translocation of 
intestinal microbiota or LPS. This may cause low-levels of systemic inflammation, which can 
affect the neuroinflammatory state (Brenchley and Douek 2012; Yarandi et al. 2016). This 
could potentially explain an increase in TREM2 in certain animals in the absence of overt 
disease. 
In general, the pattern of increased expression of TREM2 with SIV infection 
independent of ART parallels our previous report of CSF1R expression increases seen within 
the same SIV model (Knight et al. 2018). Our finding that TREM2 RNA levels were strongly 
correlated with both CSF1R and its ligand CSF1 RNA levels is consistent with previous 





and also interact with the same adapter protein, DAP12, for downstream signaling (Satoh et 
al. 2014; Guan et al. 2016; Kobayashi et al. 2016).  
Of note, treating SIV-infected pigtailed macaques with suppressive ART reduced 
brain TREM2 RNA and protein levels to baseline pre-infection values in contrast with the 
sustained elevated CSF1R protein levels that we have reported with ART (Knight et al. 
2018). This suggests that TREM2 may not play a key immunoregulatory role  in the ART era 
in contrast with previous studies (Fields et al. 2018; Gisslén et al. 2019). This finding also 
suggests that post-transcriptional regulation differentiates TREM2 from CSF1R with respect 
to duration of expression on macrophages.  This difference likely represents the different 
functional roles that these receptors play, including both trophic and immunoregulatory 
functions. The sustained increase in CSF1R protein levels with ART may represent reduced 
degradation or elevated cytosolic stores of CSF1R that are key for maintaining high CSF1R 
levels in the face of cellular stress. Additionally, slower processing of the immature CSF1R 
protein may result in a more consistently elevated level of mature CSF1R at the cell 
membrane (Uden, Morley, and Dibb 1999). This may also explain why CSF1R protein 
remains elevated without a concordant increase in CSF1R mRNA. 
We extended these findings to examine whether stopping ART treatment in SIV-
infected macaques induced expression of TREM2 during early viral rebound when SIV 
emerges from latency. Since we did not have access to acute timepoints to measure TREM2 
mRNA and protein at the earliest stage of SIV rebound, we sampled terminal timepoints in 
SIV-infected macaques released from ART. We hypothesized that TREM2 could be an early 
regulator of CNS macrophage immune activation and potentially related to viral load at post-





abundant SIV RNA in both plasma and CSF.  In contrast, we did find significantly higher 
levels of CSF1R protein in the frontal cortex during rebound similar to the sustained 
elevation of CSF1R present under long-term ART. As this rebound was relatively short 
(approximately 20 days post ART release), it is possible that TREM2 mRNA and protein 
would increase with longer reactivation. 
CSF1R signaling is essential for microglial survival and also may regulate microglial 
immune function during chronic neurodegeneration like that seen in HIV CNS disease. 
Therefore, microglia may have developed mechanisms to maintain CSF1R protein without 
activating transcription.  It is possible that herein lies the key difference in TREM2 and 
CSF1R protein levels in this model of HIV CNS disease. We hypothesize that TREM2 is a 
marker of microglial cell number that does not change at the single cell level with infection. 
CSF1R, on the other hand, may be a marker of microglial priming as CSF1R protein remains 
elevated in fully suppressed macaques after initial SIV infection. It has previously been 
shown in rodent models of acute and chronic neuroinflammation that TREM2 is a marker of 
bulk microglia whereas CSF1 correlates primarily with chronic microglial activation and 
priming, and secondarily with acute microglial immune responses (Holtman et al. 2015). 
Maintaining CSF1R protein after initial infection may allow the cell to be more prepared for 
a subsequent insult. This ultimately suggests that although both TREM2 and CSF1R are 
closely related proteins in both mRNA expression control and downstream function in 
microglia (Yeh et al. 2017; Chitu et al. 2016; Stanley and Chitu 2014), CSF1R may play a 
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Figure 3-1. TREM2 mRNA localizes to microglia and perivascular macrophages in 
pigtailed macaques. (A) TREM2 RNA in frontal cortex parenchyma in an uninfected 
pigtailed macaque. (B) TREM2 RNA increased after 42 days of SIV infection. (C) TREM2 
RNA present in a perivascular cuff of macrophages in a macaque with encephalitis. (D) 






Figure 3-2. mRNA expression of TREM2 and CSF1R increase with SIV encephalitis 
and are positively correlated with each other (A) TREM2 mRNA and (B) CSF1R mRNA 
were significantly increased in SIV-infected pigtailed macaques with encephalitis and 
returned to baseline levels with suppressive ART. Kruskal-Wallis tests with Dunn’s multiple 
comparisons were performed to determine significance. (C) TREM2 mRNA was 
significantly correlated with CSF1R and (D) CSF1 mRNA in SIV-infected macaques without 









Figure 3. PU.1 protein, a transcription factor shared by TREM2 and CSF1R, increased 
with SIV and returned to baseline with suppressive ART, in agreement with TREM2 
and CSF1R mRNA expression. (A) In uninfected macaque frontal cortex, PU.1 positive 
staining was localized to the nuclei of parenchymal microglia and perivascular macrophages. 
(B) After 84 days of SIV infection (84d SIV), there was a marked increase in the number of 
PU.1+ cells (P = 0.03). (C) PU.1+ cell numbers then returned to baseline with ART. IHC 

























Figure 3-4. TREM2 and CSF1R protein levels were discordant in SIV infected pigtailed 
macaques. (A) TREM2 protein levels were not significantly higher in SIV infected 
macaques with or without ART treatment (Kruskal-Wallis with multiple comparisons P = 
0.09) (B) Despite correlation of mRNA levels, TREM2 and CSF1R protein concentrations in 
frontal cortex of SIV infected pigtailed macaques did not correlate. All protein levels were 
used to evaluate the correlation between TREM2 and CSF1R protein expression (n = 26) 








Figure 3-5. TREM2 and CSF1R mRNA did not increase after release from suppressive 
ART. TREM2 mRNA (A, Mann-Whitney P = 0.9) and CSF1R (B, Mann-Whitney P = 0.9) 
remained at baseline after release from suppressive treatment by qPCR. PU.1 IHC 
quantification supported this finding (C). PU.1 protein did not increase with release from 
ART (Mann-Whitney P = 0.6) (A and B: Uninfected = ● n = 7; TREM2 and CSF1R Release 































































Figure 3-6. TREM2 and CSF1R protein expression after release from antiretroviral 
treatment. Like mRNA, TREM2 protein levels did not increase upon release from 
suppressive ART (A). However, CSF1R protein was higher under these conditions (B). The 
median fold change from baseline was significantly higher for CSF1R protein than TREM2 
protein (C). (A and B. SIV + ART = ◼ n =7; Release = ◆ n = 11; C. TREM2 release = ◆ n 
= 11; CSF1R Release = ◆ n = 11). 
  





















































Supplemental Table 3-1 
     
Animal ID  Age at Euthanasia (yrs)  
Inoculation 
Status Treatment  
Length of SIV 
infection (wks) 
PT247  3.5  Mock None  - 
PT248 2.9  Mock None  - 
PT249 3.1  Mock None  - 
PT290  2.5  Mock None  - 
PT293  2.3  Mock None  - 
PT332  5.0  Mock None  - 
PT334  5.1  Mock None  - 
PT373 3.5  Mock None  - 
PT374 3.5  Mock None  - 
PT437 3.2  SIV None  6 
PT439 3.1  SIV None  6 
PT438 3.1  SIV None  6 
PT441 2.4  SIV None  6 
PT440 2.9  SIV None  6 
PT442 2.2  SIV None  6 
PT300  3.2  SIV None  11 
PT265 4.7  SIV None  6 
PT353 5.3  SIV None  12 
PT298 3.1  SIV None  13 
PT291 2.5  SIV None  12 
PT203  9.5  SIV None  9 
PT320  3.6  SIV None  9 
PT297  2.5  SIV None  11 
PT274  6.2  SIV None  7 
PT394  3.8  SIV   ART*  26 
PT400  4.3  SIV   ART*  26 
PT390  4.1  SIV  ART* 26 
PT401 3.6  SIV ART* 26 
PT391  3.3  SIV ART  26 
PT392  3.2  SIV ART  26 
PT409 3.7  SIV   ART*/Release 28 
PT410 3.4  SIV   ART*/ Release 28 
PT411 3.4  SIV   ART*/ Release 27 
PT412 3.2  SIV   ART*/ Release 27 
PT413 3.1  SIV  ART*/ Release 26 
PT414 2.9  SIV   ART*/ Release 26 
PT422 3.1  SIV ART/ Release 26 





PT425 2.8  SIV ART/ Release 27 
PT424 2.8  SIV ART/ Release 28 
ART* denotes animals receiving ART+MVC  
 
Supplemental Table 3-1. Study Animals. Description of animals from which samples were 







Supplemental Figure 1: TREM2 ISH colocalizes with IBA1+ CNS macrophages. (A) 
The double IHC-ISH staining showed that TREM2 ISH (red) colocalizes with IBA1+ cells 
(brown) in an SIV infected pigtailed macaque with encephalitis. (B) Fluorescence was used 















































CNS macrophages, including microglia, serve as a latent HIV cellular reservoir. 
Colony stimulating factor 1 receptor (CSF1R) is expressed exclusively on cells of myeloid 
lineage and is essential for microglial survival. We have previously shown that CSF1R 
protein levels increase with SIV infection and remain elevated in the CNS despite 
suppressive ART. Other groups have described the same pattern of CSF1R protein 
expression with HIV infection. Consequently, CSF1R is a potential drug target to reduce the 
CNS latent reservoir. PLX3397 (Pexidartinib) is an FDA-approved, small-molecule inhibitor 
of CSF1R and has been shown to effectively eliminate microglia in rodent models in vivo. To 
determine whether CSF1R inhibition in primates would result in microglia depletion, we 
cultured primary brain and spinal cord microglia and then treated cells with 10µM PLX3397 
for three days. Microglial viability was significantly reduced as observed by calcein (live) 
and ethidium (dead) staining, as well as interferon-beta qPCR (Two-Way ANOVA P < 
0.0001). Following in vitro treatment, in vivo studies were conducted using daily oral 
treatment of 165mg/kg PLX3397 in ART-suppressed SIV-infected pigtailed macaques (N = 
2). Two weeks after the start of PLX3397 treatment, ART was stopped while PLX3397 
treatment continued for an additional 16 days. Drug treatment was well tolerated; animals did 
not show side-effects such as monocytopenia. PLX3397 treatment did not significantly affect 
plasma viral rebound kinetics. However, CSF viral rebound did not develop in one animal. In 
addition, neither SIV RNA nor DNA was detected in cultured primary microglia from this 
animal. In the second animal, viral RNA was isolated from CNS macrophages cultured from 
both brain and spinal cord. These studies showed that PLX3397 reduced CNS macrophage 





including those harboring HIV. Treatment of SIV-infected macaques on ART was associated 
with a lack of SIV rebound from the CNS and a decrease in IBA1+ CNS macrophages in one 
of two animals after stopping ART. These studies demonstrate the potential of targeting 







Central nervous system macrophages, including microglia, have been associated with 
the development of several neurodegenerative diseases, including HIV associated CNS 
disease (Cartier et al. 2014; Saylor et al. 2016; Williams et al. 2014). In HIV CNS disease, 
microglia are chronically activated, even in the context of full viral suppression using 
antiretroviral therapy (ART). This chronic immune activation is thought to drive neuronal 
damage and consequently CNS impairment (Saylor et al. 2016; Williams et al. 2014). 
Beyond the effects of chronic immune activation, microglia are also essential in the 
development of the viral reservoir within the brain. In the brain, microglia are the main cell 
infected by HIV that harbor and produce infection-competent virus (Abreu et al. 2019; 
Wallet et al. 2019). Consequently, targeting microglia is important not only for the potential 
treatment of HIV-induced neurologic disease, but also for eliminating HIV from the CNS to 
achieve cure.  
Colony stimulating factor 1 receptor is a classic tyrosine kinase receptor 
constitutively expressed on cells of the myeloid lineage. In the central nervous system, it is 
exclusively expressed on microglia and perivascular macrophages (Chitu et al. 2016). CSF1R 
signaling is essential for microglial survival and proliferation (Elmore et al. 2014; Stanley 
and Chitu 2014). Previous evidence suggests that CSF1R signaling may impact microglial 
immune responses as well (Coleman et al. 2020). Increased levels of CSF1R have been 
reported in several neurodegenerative diseases, including Alzheimer’s disease (AD), 
amyotrophic lateral sclerosis (ALS), and other neuroinflammatory diseases such as prion 
disease (Akiyama et al. 1994; Gomez-Nicola et al. 2013; Mitrasinovic and Murphy 2003). 





models of AD and in post-mortem human brain samples (Akiyama et al. 1994; Dagher et al. 
2015). A recent GWAS study identified a mutation in CSF1R that led to increased basal 
levels that increased the risk of developing early-onset AD (Sassi et al. 2018). Beyond AD, 
we have shown that CSF1R expression increases in an SIV/macaque model of HIV CNS 
disease during SIV encephalitis and remains elevated when animals are suppressed with ART 
(Knight et al. 2018). Because of the association between increased CSF1R expression and 
neurodegenerative disease, targeting this receptor is of particular interest.  
PLX3397 is a small molecule inhibitor of CSF1R that has recently received FDA 
approval for the treatment of tenosynovial giant-cell tumors (Lamb 2019). PLX3397 
treatment effectively kills CSF1R-expressing tumor associated macrophages (TAMs) in these 
tumors (Tap et al. 2015). These cells are thought to promote tumorigenesis (Cannarile et al. 
2017). However, in other cancers there is some debate as to whether PLX3397 depletes 
TAMs or alters the phenotype of these cells (Dammeijer et al. 2017; Ao et al. 2017). CSF1R 
inhibitors, including PLX3397, have also been used in multiple rodent models of 
neurodegenerative diseases, including AD, ALS, and MS (Mancuso et al. 2019; Olmos-
Alonso et al. 2016; Spangenberg et al. 2016; Dagher et al. 2015;  Martinez-Muriana et al. 
2016; Tahmasebi et al. 2019; Beckmann et al. 2018; Nissen et al. 2018). In mouse models, 
CSF1R inhibition depletes microglia to varying degrees (Han et al. 2017). PLX3397 is the 
most effective of these inhibitors, depleting at least 90% of microglia (Han et al. 2017; 
Elmore et al. 2015; Jin et al. 2017; Li et al. 2017; Szalay et al. 2016). 
Because of its efficacy, FDA approval, and ability to penetrate the blood-brain barrier 
(BBB), we evaluated the ability of PLX3397 to inhibit CSF1R signaling in our SIV/pigtailed 





reduce the number of microglia in vitro and in vivo in this model by blocking a vital trophic 
signaling pathway. Consequently, we proposed that by reducing the number of microglia, the 
SIV latent reservoir in the CNS would also be reduced. Here, we show that CSF1R inhibition 
quickly depleted primary pigtailed macaque microglia in vitro. However, PLX3397 treatment 
did not significantly deplete microglia in vivo. Interestingly, PLX3397 did prevent viral 
rebound in a PLX3397-treated animal after it was released from ART. This suggests that 
when activated, nonhuman primate microglia require CSF1R signaling for survival; in resting 
or primed microglia, inhibiting CSF1R signaling may alter the immunophenotype of these 
cells rather than killing the cell. These findings also reflect that maximal dosing was not 
achieved in this study. Also, CSF1R inhibition may be an effective way to reduce, and 




























Male juvenile specific-pathogen-free pigtailed macaques (Macaca nemestrina) were 
included in this study. Animals were screened for Macacine herpesvirus 1 (B virus), simian 
immunodeficiency virus (SIV), simian T-cell leukemia virus (STLV-1), and simian retrovirus 
(SRV). At necropsy, animals were perfused with phosphate-buffered saline. Sections of the 
brain were serially sectioned and were flash-frozen or fixed in Streck tissue fixative (STF). 
Remaining brain tissue was used to isolate microglia.  
 For PLX3397 in vitro experiments, microglia were isolated from three uninfected 
pigtailed macaques. These animals were mock inoculated with Lactated Ringers Solution 
(LRS) and euthanized 84 days after mock inoculation.  
 Eight animals were intravenously infected with two strains of SIV: SIV/17E-Fr and 
SIV/DeltaB670. SIV/17E-Fr is a neurovirulent molecular clone, while SIV/DeltaB670 is an 
immunosuppressive swarm. At 12 days post-infection (dpi), animals were treated daily with a 
subcutaneous injection of a combination of 2.5 mg/kg Dolutegravir (ViiV Healthcare US, 
Raleigh, NC), 20 mg/kg PMPA, and 40 mg/kg FTC (Gilead, Foster City, CA). They were 
also treated with a daily oral dose of 20 mg of Maraviroc (ViiV Healthcare US, Raleigh, 
NC). Animals were fully suppressed for 120 days. At this time, they were released from ART 
and euthanized at viral set point (Release group). This was defined as three cumulative 
plasma viral loads within one log of each other. Typically, this point was reached within 20 
days post-release. Plasma and CSF were collected every four days post-ART release to 





Two of the 8 animals were also given a daily 165 mg/kg oral dose of PLX3397 
starting two weeks prior to ART release (PLX3397-treated group). Dosing was based upon 
previously published pharmacokinetic studies (Tap et al. 2015). PLX3397 treatment 
continued for two weeks after ART was removed, at which time the animals were euthanized 
(Figure 1). One animal, PLX2, was euthanized 16 days post ART release when it developed 
significant weight loss.  
All animal studies were approved by the Johns Hopkins Animal Care and Use 
Committee. 
 
Microglia isolation  
Microglia were isolated from the brains of two PLX3397-treated animals, 2 
uninfected, untreated animals, and 1 SIV-infected, untreated animal euthanized 84 days post-
infection. After sectioning, remaining pieces encompassing every section of the brain were 
used. Meninges were removed from CNS tissue. Tissue was minced and then centrifuged 
twice in PBS for 3 minutes at 400xg at room temperature. The tissue was then incubated in 
Dulbecco’s modified Eagle (DMEM) media (Life Technologies, Carlsbad, CA) 
supplemented with 0.25% trypsin, 50µM DNase/mL and 50µg gentamicin/mL solution at 
37°C for 30 minutes. Fifteen minutes into the incubation, the slurry was briefly agitated and 
then returned to the water bath. This slurry was then filtered through a 183µM pore filter and 
then a 100µM pore mesh in DMEM supplemented with fetal bovine serum (FBS), at a final 
concentration of 10%, to remove undigested tissue fragments. This filtrate was centrifuged 
for 10 minutes at 400xg at room temperature. The resultant cell pellet was resuspended in 





minutes at room temperature. The supernatant below the myelin cap was then removed and 
spun down for 10 minutes at 400xg at room temperature to isolate the cell pellet free from 
myelin. Cells were then plated at in DMEM supplemented with FBS at a 10% concentration. 
After 24 hours, wells were washed with DMEM 10 to remove unattached cells and the 
remaining adherent cells were then cultured in microglia media composed of DMEM (Life 
Technologies, Carlsbad, CA) supplemented with 50µg gentamycin/mL (Life Technologies, 
Carlsbad, CA), 1mM sodium pyruvate, 10% volume of 100% FBS (ThermoFisher Scientific, 
Waltham, MA), and 10% volume of giant cell tumor conditioned medium(Fisher Scientific, 
Hampton, NH) (Alvalos et al. 2017).  
 
SIV RNA quantification 
 SIV RNA was quantified in plasma and CSF by qRT-PCR and ddPCR as previously 
described (Abreu et al. 2019; Barber et al. 2004; Beck et al. 2015; Witwer et al. 2009). 
 SIV RNA levels in cell culture supernatants were quantified by qRT-PCR as 
previously reported (Abreu et al. 2019). Cells were left in culture for seven days before 
supernatant collection began. Half-volume supernatants were then collected every two days; 
the amount of microglia media sampled was then replaced after sampling. SIV was isolated 
from supernatants using QIAmp MinElute Virus Spin Kit according to manufacturer’s 
protocol (Qiagen, Frederick, MD).  
Because early timepoints for microglia isolated from PLX2 were negative for SIV 
RNA, cells were stimulated with 10ng/mL of TNF-a (ProSpec, East Brunswick, NJ) for 48 






PLX3397 in vitro treatment 
 Microglia from the brains of two uninfected pigtailed macaques and one untreated 
SIV-infected pigtailed macaque euthanized 84 dpi were utilized for these experiments. After 
isolation, adherent cells were left in culture for seven days before treatment. Cells were then 
treated once daily with 10µM PLX3397 in DMSO or vehicle alone (DMSO). For each 
experiment, four wells of microglia were used. The first well was collected before treatment 
to determine the baseline number of cells. Each subsequent well was collected at 24, 48, and 
72 hours post-PLX3397 treatment (Supplemental Figure 4-1). Lysates were collected in 
RLT+ buffer (Qiagen, Frederick, MD) and stored at -80°C for cell count analysis. Brightfield 
images were taken at 100X and 200X at each timepoint using the Nikon H600L inverted 
microscope.  
 DNA was then isolated from cell lysates to determine total cell number in each well. 
The number of cells remaining in the well at each timepoint was determined by interferon 
beta qPCR as previously described (Abreu et al. 2019), enabling quantitative assessments 
that complemented visual comparisons of microglia density with and without PLX3397 
treatment. 
 
Cell viability immunofluorescence 
 Live versus dead cell staining was performed at each timepoint. Each timepoint 
represents a different well as represented in Supplemental Figure 4-1. Live cells were 
labeled with calcein and dead cells labeled with ethidium as previously described (Bohlen et 







IBA1 Immunohistochemistry  
 Frontal cortex, occipital cortex, and parietal cortex sections immersion fixed in Streck 
tissue fixative from PLX3997-treated and release groups were stained with anti-IBA1 
antibody (cat. 019-19741, Wako, Richmond, VA) at a dilution of 1:500. Slides were 
counterstained with hematoxylin. All slides were stained using the Leica Bond RX 
automated system with the Bond Polymer Refine Red kit (Leica Biosystems, Richmond, IL). 
Heat-induced epitope retrieval was performed at 100°C for 20 minutes in sodium citrate-
based ER1 buffer (Leica Biosystems, Richmond, IL). Images were acquired using Nikon 










PLX3397 treatment kills pigtailed macaque microglia in vitro 
 
Previous reports have shown that PLX3397 treatment effectively kills human 
macrophages in vitro (Ao et al. 2017; Cunyat et al. 2016). However, the effects of PLX3397 
on nonhuman primate microglia have not been determined in vitro. Based on the previously 
published report of PLX3397 treatment on human macrophages infected with HIV, we 
treated primary microglia isolated from uninfected pigtailed macaques with 10µM PLX3397 
in DMSO or vehicle alone once daily over the course of 72 hours (Cunyat et al. 2016). At 24 
hours, there was a clear decrease in the number of microglia in the treated group (Figure 4-
2A). The number of microglia continued to decline at 48 hours (Figure 4-2A). Depletion was 
maximal after 72 hours of treatment with loss of 84% of microglia from baseline. This 
decrease was statistically significant (Figure 4-2B; P = 0.03 Sidak’s multiple comparisons) 
Two-way ANOVA revealed that time and treatment were driving this decline in microglia 
from baseline (P < 0.0001).  
This was further confirmed using fluorescent live/dead staining. Live cells were 
stained with calcein (green) and dead cells were labeled with ethidium (red). At 48 hours 
post-treatment, there were no dead cells in the vehicle treated well (Figure 4-3A). However, 
there were detectable dead cells in the PLX3397 treated well (Figure 4-3B, red 
arrowheads). The live cell staining also highlighted the clear difference in cell morphology 
in the PLX3397 treated cells compared to the vehicle treated cells. PLX3397 treatment 
resulted in smaller cell size and it causes microglia to cluster and bind together, characteristic 





and ethidium (Figure 4-3B, yellow arrowhead). These cells were likely in the process of 
dying. 
 
The effects of PLX3397 treatment on SIV viral rebound kinetics in plasma and CSF 
 It has been previously reported that PLX3397 treatment eliminated over 90% of 
microglia in the rodent brain (Elmore et al. 2015; Jin et al. 2017; Li et al. 2017; Szalay et al. 
2016). However, studies of PLX3397 in nonhuman primates have been limited to drug 
tolerance and PK/PD characterization (Tap et al. 2015). Here, we evaluated the effects of 
PLX3397 in SIV-infected pigtailed macaques. We treated fully-suppressed pigtailed 
macaques with 165 mg/kg of oral PLX3397 once daily for two weeks. We then released 
these two animals from their ART regimen but maintained PLX3397 treatment (Figure 4-1). 
Paired plasma and CSF samples were collected every 4 days post-release from ART to 
characterize the viral rebound kinetics.  
 The drug dose was well-tolerated by the animals with no side-effects noted. 
Additionally, no monocytopenia developed in either animal (data not shown). After release 
from ART, SIV RNA was detected in the plasma of both animals and the rebound trajectory 
was not different from PLX3397-naive animals released from ART (Figure 4-4A). In animal 
PLX1, viral rebound in the cerebrospinal fluid (CSF) was detected 12 days post-ART release, 
and the rebound trajectory matched the PLX3397-naïve animals. However, PLX2 had no 
detectable virus in CSF at any timepoint before euthanasia at 16 days post-release from ART 
(Figure 4-4B). This suggests that PLX3397 has the potential to suppress viral rebound 






PLX3397 prevented viral outgrowth in the primary microglia isolated from one animal 
 Since microglia are thought to be a significant contributor to SIV viral load in the 
CSF, we isolated primary microglia from PLX3397-treated animals to determine if SIV RNA 
was detectable. In both animals, approximately half of the number of microglia were isolated 
compared to uninfected control pigtailed macaques (data not included). These microglia were 
cultured, and cell culture supernatants were sampled for SIV RNA. Microglia cell culture 
supernatant was sampled for 12 days. In PLX1, virus was detectable by qRT-PCR at the first 
sampled timepoint after 7 days in culture (Figure 4-5). Virus remained detectable until the 
termination of sampling at day 14. However, SIV RNA was not detected in microglia cell 
culture supernatants isolated from PLX2 after 12 days in culture (Figure 4-5). This shows 
the potential for PLX3397 treatment to reduce the CNS SIV reservoir. 
  
PLX3397 treatment affected microglial morphology in vivo 
PLX3397 significantly reduced the number of microglia in brains of mice (Han et al. 
2017; Elmore et al. 2015; Jin et al. 2017; Li et al. 2017; Szalay et al. 2016). To determine 
whether PLX3397 treatment affected microglial numbers in nonhuman primates similarly, 
IBA1 immunohistochemistry was performed on frontal cortex, occipital cortex, and parietal 
cortex of PLX3397 treated animals and release animals. In both PLX1 and PLX2, there were 
clearly detectable IBA1+ microglia in grey and white matter sections in all brain regions 
stained. However, there were visually fewer microglia in these sections compared to release 
animals. 
In frontal cortex white matter especially, there was a clear reduction in microglia in 





addition to this visual reduction in microglial number, there was a clear difference in 
microglial morphology in PLX3397-treated animals compared to release animals. The 
microglia in the ART-release animal frontal cortex show a more ameboid morphology, 
representing an activated state. However, the microglia in both PLX3397-treated animals had 
clear, long, ramified projections, which are characteristic of a surveilling or resting 
immunophenotype (Figure 4-6; Hanisch and Kettenmann 2007; Kreutzberg 1996). This 
suggests that PLX3397 had an effect on nonhuman primates in vivo, as evidenced by reduced 







 We described the effects of PLX3397 on pigtailed macaque microglia both in vitro 
and in vivo. As previously reported with human macrophages, we showed that PLX3397 
effectively kills pigtailed macaque microglia in vitro at a concentration of 10µM (Cunyat et 
al. 2016). Approximately 84% of microglia were depleted in vitro after 72 hours. It is 
possible that with more time, the percent depletion would reach that seen in mice in vivo 
(Han et al. 2017; Elmore et al. 2015; Jin et al. 2017; Li et al. 2017; Szalay et al. 2016).   
 While PLX3397 did not deplete microglia in pigtailed macaques to the extent seen in 
mice, it did reduce microglial number in SIV-infected pigtailed macaques. The lack of total 
depletion of microglia in PLX3397-treated pigtailed macaques may be due to a lack of 
efficient and maximal drug penetrance. The dosage selected for this pilot trial was based on a 
single preclinical study conducted in a cynomolgus macaque (Tap et al. 2015). In this 
previously published study, there were high concentrations of drug in both plasma and CSF, 
showing efficient drug absorption from oral dosing. However, it is not clear whether the 
pigtailed macaques in this study reached similar drug concentrations. Further PK/PD studies 
will need to be conducted to determine the proper drug dosing strategy. 
Beyond a lack of drug penetration, this lack of total depletion of microglia may be 
specific to primates. The effect of PLX3397 on primate microglia has not been evaluated 
outside of this study. Recent reports show that rodent microglia are significantly different in 
function compared to primate microglia (Geirsdottir et al. 2019). Consequently, primate 
microglia may not be as reliant on CSF1R signaling for survival as rodent microglia. 
Despite this lack of depletion, it is clear that PLX3397 did have an effect on pigtailed 





This change in morphology may represent a change in microglial phenotype (Hanisch and 
Kettenmann 2007; Kreutzberg 1996). Previously, we hypothesized that microglia in our fully 
suppressed animals may be primed from previous exposure to replicating SIV or continued 
exposure to viral proteins. We also hypothesized that CSF1R signaling may be important in 
this primed state (Chapter III; Figure 1-4). Consequently, this return to a resting 
morphology in PLX3397-treated animals may be a result of inhibiting CSF1R signaling and 
subsequently changing in microglial phenotype. A previous study did note that CSF1R 
inhibition resulted in the resetting of primed microglia to a resting state (Coleman et al. 
2016). Further single-cell sequencing studies of these microglia will be necessary to confirm 
this in our model.  
 Interestingly, although released from ART, there was no evidence of viral rebound in 
the CSF of PLX2. This may be due to a reduction in the viral reservoir in the CNS. Although 
not significant, there was a reduction in the number of microglia that was more apparent in 
PLX2 than in PLX1. It is possible that if this study were extended, PLX2 would eventually 
rebound in the CSF. However, this delay is important to note, as it may represent a reduction 
in the latent reservoir. It is also interesting to note that PLX3397 treatment had no effect on 
plasma viral rebound. This shows that PLX3397 may target the CNS reservoir rather than in 
other tissues. 
 Overall, PLX3397 treatment was more effective in PLX2 than in PLX1. One possible 
explanation for this difference is that PLX2 had a lower body fat content than PLX1, 
enhancing drug distribution to the CNS in this animal. Measuring drug concentration in both 
body fat and in the brain will be required to examine this difference in future studies. 





effective at reducing the SIV viral reservoir in the brain. PLX3397 may be an effective 
treatment to reduce the viral reservoir in the CNS and also reset primed microglia to a resting 







Figure 4-1. In vivo treatment protocol. Animals were IV inoculated with SIV/17EFr and 
SIV/DeltaB670. Infected animals were then treated with ART as described. Two weeks 
preceding withdrawal from ART regimen, animals PLX1 and PLX2 were treated with 
165mg/kg PLX3397. PLX3397 was maintained until the animals were euthanized post ART 






















































Figure 4-2: 72 hours of PLX3397 treatment depletes microglia in vitro. Uninfected 
pigtailed macaque microglia were treated daily with 10µM PLX3397 in DMSO or with 
vehicle (DMSO) alone. (A) Phase microscopy showed a visible decrease in cell number over 
48 hours of PLX3397 treatment compared to vehicle control. (B) Cell counts were 
determined with interferon-beta qPCR. After 72 hours of PLX3397 treatment, microglia cell 
number decreased approximately 84% from baseline. This decrease was significant (P = 
0.03, Sidak’s multiple comparisons test) and was due to PLX3397 treatment over time (Two-







Figure 4-3. PLX3397 kills primary pigtailed macaque microglia in vitro. Primary 
microglia isolated from an uninfected pigtailed macaque were treated for 48 hours with 
vehicle (DMSO) (A) or 10µM PLX3397 (B). Live microglia were identified with the uptake 
of calcein (green), and dead cells were identified with the uptake of ethidium homodimer 
(red). PLX3397 treatment (B) killed cells, and the remaining live cells were smaller and 







Figure 4-4. The effect of PLX3397 on plasma and CSF viral rebound kinetics in SIV-
infected macaques released from ART. (A) The kinetics of viral rebound in the plasma of 
PLX3397 treated animals was no different compared to procedural control animals (Release). 
(B) While the viral rebound kinetics in the CSF was not affected in PLX1, CSF viral rebound 
did not occur in PLX2 16 days post-release from ART.  
  


























































Figure 4-5. Viral outgrowth of microglia isolated from SIV-infected macaques treated 
with PLX3397 and released from ART. Virus RNA was detectable in the supernatants of 
microglia isolated from the brain of PLX1 (black). However, virus RNA was undetectable in 
the supernatants of microglia isolated from the brain of PLX2 (blue). Limit of quantitation 













































Figure 4-6. The effect of PLX3397 treatment on microglial viability in vivo. IBA1+ 
immunostaining (red) in frontal cortex white matter of PLX1 showed a change in microglial 
morphology, including enlarged nuclei and longer projections compared to procedural 
controls (Release group as detailed in methods). In PLX2, there was a reduction in IBA1+ 
staining compared to procedural controls. Additionally, the microglia remaining had similar 








Supplemental Figure 4-1. Microglia in vitro experiment template. For all microglia in 
vitro experiments described, microglia were plated in four wells of a six-well plate in 
duplicate. Brightfield images, live/dead immunofluorescence staining and imaging, and cell 
































HIV associated neurocognitive disorders (HAND) remain a significant issue in the 
ART era (Saylor et al. 2016). The work presented here elucidated the role of chronic 
microglial activation, specifically via colony stimulating factor 1 (CSF1) and its receptor 
colony stimulating factor 1 receptor (CSF1R), in HAND using an accelerated SIV/pigtailed 
macaque model of HIV CNS disease (Beck et al. 2015; Beck et al. 2018; Beck et al. 2015). 
In Chapter II, we showed that in this model, CSF1 mRNA levels were significantly 
increased with the development of SIV encephalitis in the frontal cortex, and this increase 
was strongly positively correlated with several genes associated with increased stress and 
immune activation in the brain. CSF1R protein levels were also significantly increased in the 
frontal cortex with SIV encephalitis. Interestingly, this increase in CSF1R protein levels 
continued despite suppressive ART.  
Chapter III further illustrated microglial responses to chronic SIV infection in the 
brain. Here I explored expression changes of TREM2, a receptor with several of the same 
downstream effects of CSF1R signaling and similarly associated with neurodegenerative 
diseases (Yeh et al. 2017; Akiyama et al. 1996). TREM2 mRNA was significantly increased 
after 84 days of SIV infection in the brain. TREM2 mRNA was also significantly positively 
correlated with CSF1 and CSF1R. However, unlike CSF1R, TREM2 protein returned to 
baseline with suppressive ART. Therefore, although similar, TREM2 and CSF1R have 
distinct roles in CNS inflammation, specifically in the context of chronic SIV infection.  
Interestingly, while CSF1R protein remained elevated with suppressive ART, CSF1R 
mRNA returned to baseline in these animals. This suggests that post-translational 
modifications or decreased protein degradation maintained CSF1R in this chronically 





priming. Microglial priming is a type of innate immune memory, in which microglia that 
have responded to an insult in the past will respond stronger and faster to a second insult. 
Because of this, these primed microglia can cause more damage to less stimulus (Neher and 
Cunningham 2019). Thus, CSF1R may also be a target for suppressing chronic immune 
stimulation that persists in the CNS despite ART. 
In Chapter IV, we showed evidence that CSF1R is an intriguing target to remove the 
latent SIV reservoir in the brain and reset primed microglia. The small molecule CSF1R 
inhibitor, PLX3397, effectively killed primary pigtailed macaque microglia in vitro. In vivo, 
PLX3397 treatment of SIV infected macaques prevented viral rebound in the CSF in one of 
two animals. This suggested that CSF1R inhibition can reduce the latent viral reservoir in the 
brain. PLX3397 treatment consistently reduced the number of microglia in rodent brain over 
90% (Han et al. 2017; Elmore et al. 2015; Jin et al. 2017; Li et al. 2017; Szalay et al. 2016). 
While this was the case for nonhuman primate microglia in vitro, microglia were not 
depleted to this extent in vivo. This is likely because maximal drug concentrations were not 
achieved in this preliminary study. It is also important to note that rodent microglia and 
primate microglia, including human microglia, are quite different (Geirsdottir et al 2019). 
There is a core signature of microglia genes across species, including classic markers of 
microglia, such as SPI1, P2RY12, and TREM2. However, metabolic and immune pathway 
genes diverge from rodents to primates. Importantly, genes associated with 
neurodegeneration in humans were poorly correlated with those seen in mouse models of 
these diseases. Macaque microglial signatures, however, were closely correlated to those in 
human Alzheimer’s disease and Parkinson’s disease (Geirsdottir et al. 2019). Consequently, 





primates. When plated, microglia adopt an activated immunophenotype (Bohlen et al 2017). 
Thus, we hypothesize that CSF1R signaling is essential for the survival of activated 
microglia, but resting microglia may not be as sensitive to CSF1R inhibition. 
Interestingly, the microglia that remained had a different morphology compared to 
other animals released from ART. These microglia had longer, more branched projections, 
representing a surveilling or resting phenotype compared to the ameboid, activated 
phenotype seen in the other SIV-infected release animals (Hanisch and Kettenmann 2007; 
Kreutzberg 1996). This suggests that CSF1R signaling is also important for microglial 
activation and immune responses in addition to survival. It has also been proposed that in 
addition to depleting microglia, CSF1R inhibition ‘stuns’ microglia, preventing microglial 
replication (Gerber et al 2018). Future studies with BrdU labeling would be necessary to 
determine changes in microglial replication in PLX3397-treated SIV-infected animals.    
Ongoing, we will determine how CSF1R signaling directly impacts microglial 
phenotype and immune responses including obtaining single-cell RNA sequencing microglia 
data from PLX3397 treated and untreated animals. We are also interested in identifying the 
chronic transcriptomic perturbances present in fully suppressed, SIV-infected brain. It has 
been inferred that chronic inflammation is a major contributor to CNS impairment in fully 
suppressed HIV infected individuals (Saylor et al. 2016). However, the field’s ability to 
identify clear therapeutic targets and consistent changes is limited by a lack of access to 
tissues from persons living with HIV. We are performing whole transcriptome sequencing of 
basal ganglia from SIV/macaque groups outlined in Table 5-1.  
There are several limitations to doing bulk tissue RNA sequencing in the brain when 





is primarily due to the low percentage of microglial cells in the brain compared to other cells 
(Lawson et al 1990). To circumvent this limitation, we will be projecting our RNA-
sequencing data into single cell transcriptome datasets previously published (Cahoy et al 
2008; Li et al 2019; Zamanian et al 2008). Projection analysis allows gene expression data 
from other related experiments to be visualized, or “projected”, into dimensions defined by 
the dataset of interest (Stein-O’Brien et al. 2019; Sharma et al 2020). We will perform 
several analyses, including principal component analysis (PCA), clustering, and non-negative 
matrix factorization (NMF). These analyses will define the dimensions that we will then be 
able to project into single-cell sequencing datasets as well as other neurodegenerative disease 
sequencing datasets.  
To test the efficacy of projecting our pigtailed macaque sequencing datasets into 
human data, we projected the PCA from our Nanostring dataset described in Chapter II into 
HIV data. As we saw from the Nanostring panel described in Chapter II (Knight et al. 2018; 
Meulendyke et al. 2014), SOD2 and GFAP mRNA counts were significantly upregulated 
after 84 days of SIV infection (Figure 5-1A, B; P = 0.002 and P = 0.03 respectively). To 
determine whether these changes also occurred in individuals infected with HIV, we utilized 
the National NeuroAIDS Tissue Consortium brain microarray data previously published 
(Gelman et al. 2012). SOD2 (Figure 5-1C; P = 0.001) and GFAP (Figure 5-1D; P = 0.0002) 
expression was also significantly increased in individuals with HIV encephalitis (HIVE) 
compared to uninfected individuals. 
While this shows similarities in transcriptional changes in SIVE and HIVE, this 
method is restricted to interrogating a few genes. To be able to determine transcriptional 





component analysis (PCA) on the normalized Nanostring expression data using the prcomp(.) 
function with centering, but not scaling, in R. For this analysis, we utilized data from two 
groups: uninfected controls and SIV infected animals with encephalitis. One gene was 
removed (MAP2) from this analysis because one of the uninfected controls was not 
sequenced for this gene.  PC1 accounted for 79.1% of the variance between samples, while 
PC2 accounted for 9.15% of the variance (Figure 5-2A and data not shown). The SIV group 
clusters away from the uninfected controls along PC1. Additionally, SIV animals without 
encephalitis (negative) clustered closer to the uninfected animals than the SIV 84d animals 
with encephalitis. The weights for individual genes in this PC1 indicate the extent to which 
each gene contributes to this major trajectory of expression change in SIV infection. Among 
the individual genes driving PC1, B2M (MHC I), SOD2 and GFAP were among the top 3 
differentially expressed genes (gene weights for PC1 and uncorrected Mann-Whitney p-
values listed in Supplemental Table 1).  
Using weights from this PCA, data from other experiments can be projected into this 
low-dimensional space defined by SIV infection expression change. Gene expression data 
from HIV infection (Gelman et al. 2012) was projected into the SIV PC1 using projectR 
(https://github.com/genesofeve/projectoR ; Stein-O’Brien et al. 2019; Sharma et al 2020). 
Two of the four groups (uninfected and HIVE) in the National NeuroAIDS Tissue 
Consortium (NNTC) brain microarray previously published (Gelman et al. 2012) were 
included in this analysis. To relate the dynamics of this SIV infection model to HIV 
infection, we projected gene expression data from uninfected and HIV-infected with 
encephalitis (HIVE) postmortem brain tissue (Gelman et al. 2012) into the transcriptional 





2019; Sharma et al 2020).  This projection produced a clear separation between the HIVE 
samples and the uninfected control samples (Figure 5-2B). The genes primarily driving this 
separation are again B2M, SOD2 and GFAP (Supplemental Table 1). Consequently, 
expression changes in B2M, SOD2, and GFAP are characteristic of both SIV encephalitis and 
HIV encephalitis. This also highlights a similar transcriptional program change occurring in 
both SIVE and HIVE.  
This pilot shows that we can utilize this method to gain insights into transcriptomic 
changes in our pigtailed macaque model of HIV CNS disease. We are particularly interested 
in cell-specific transcriptomic alterations, in particular microglial changes. This method is 
also useful for identifying those changes by projecting into single cell sequencing datasets. In 
this way, we will be able to determine specific microglial transcriptomic changes in bulk 
tissue RNA sequencing. By better understanding the underlying transcriptomic changes, we 
will be able to identify new therapeutic targets that may alleviate symptoms and halt the 
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Figure 5-1. SOD2 and GFAP increase in the brain with SIV and HIV encephalitis. (A) 
SOD2 mRNA counts in the Nanostring panel are significantly increased with SIV infection 
at 84 days post infection (dpi) (P = 0.002, Mann-Whitney). Open symbols represent SIV-
infected animals without encephalitis and have the lowest expression of SOD2. (B) GFAP 
also increases with SIV at 84dpi (P = 0.03) and is not as elevated in animals without 
encephalitis (No encephalitis = ▽; Encephalitis = ▲). Similarly, in HIV encephalitis, SOD2 
(C) and GFAP (D) are significantly increased compared to uninfected individuals (P = 0.001, 













Figure 5-2. Principal component analysis and subsequent projection from a pigtailed 
macaque Nanostring panel into a microarray of human brain samples reveals a 
common transcriptional program in SIV encephalitis and HIV encephalitis. (A) The first 
principal component of the PCA from the Nanostring panel separated pigtailed macaques 
based on SIV encephalitis status. Top genes driving this PC were B2M, GFAP, and SOD2. 
(B) When this PC was projected into the HIV dataset, it similarly separated samples based on 
HIV encephalitis status.  
  



































Supplemental Table 5-1 
 
Gene SIV.MannWhitney.p HIV.MannWhitney.p PC1.weight 
B2M 4.57E-05 2.31E-08 0.735169457 
GFAP 5.48E-04 2.31E-04 0.54268943 
SOD2 4.57E-05 1.35E-03 0.296681069 
UBC 4.57E-05 2.59E-01 0.157194288 
MX1 4.46E-04 1.87E-07 0.122299989 
SIV17E 4.22E-04 NA 0.082118928 
CXCL10 4.57E-05 2.33E-06 0.040687098 
SLC1A3 5.45E-02 3.64E-02 0.036079262 
STAT1 4.57E-05 9.80E-07 0.031145509 
GLUL 4.39E-03 5.19E-03 0.027469492 
ACTB 2.66E-02 7.08E-01 0.019467035 
CCL2 4.46E-04 6.29E-04 0.016499187 
CD163 4.57E-05 4.58E-03 0.014398034 
MAOB 1.37E-03 2.02E-02 0.013546421 
VCAM1 4.46E-04 8.59E-04 0.013346693 
GPX1 4.57E-05 1.06E-02 0.012288761 
CCL8 4.43E-04 3.07E-06 0.010320694 
PRDX1 1.37E-03 1.90E-01 0.010304154 
IRF1 4.46E-04 9.80E-07 0.008489555 
SOD1 8.31E-02 8.17E-01 0.007267817 
SOD3 4.57E-05 5.32E-01 0.006597271 
PRDX6 1.55E-02 5.87E-03 0.006594438 
STAT3 4.57E-05 2.33E-06 0.006339418 
STAT2 4.46E-04 4.55E-04 0.005707637 
TGFB2 9.14E-05 2.10E-04 0.005457601 
SAMHD1 4.57E-05 6.29E-04 0.005446866 
CD68 4.57E-05 4.03E-03 0.004846397 
CD14 4.57E-05 1.18E-02 0.004794605 
TXN 3.15E-01 4.21E-01 0.004664084 
IDO1 4.40E-04 4.21E-01 0.004528903 
PECAM1 4.57E-05 5.19E-03 0.004461488 
ALOX5AP 4.46E-04 9.30E-02 0.004397729 
CXCL11 4.40E-04 1.79E-03 0.004291584 
ICAM1 4.46E-04 3.81E-01 0.004052754 
IL18BP 4.57E-05 1.39E-02 0.003953579 





CXCL3 4.43E-04 7.35E-02 0.003933452 
CSF1 4.57E-05 5.18E-06 0.003620457 
CXCL2 4.46E-04 3.86E-04 0.003573592 
CCL3 4.40E-04 8.60E-02 0.003557519 
GLRX 4.57E-05 2.15E-01 0.00338539 
SOCS3 4.37E-04 1.87E-03 0.003308956 
CLEC4A 4.46E-04 2.29E-01 0.003153184 
MAOA 6.19E-02 1.45E-01 0.002852908 
TLR2 4.43E-04 6.63E-03 0.002671742 
TXNRD1 1.37E-03 3.01E-02 0.002645311 
IRF3 2.16E-03 1.61E-04 0.002565541 
TLR4 3.20E-04 9.43E-03 0.002329879 
ZFP36 4.46E-04 1.00E-03 0.00211074 
GPX3 9.29E-01 9.29E-01 0.002097262 
CXCL9 4.40E-04 1.26E-01 0.002026642 
ITGAM 4.46E-04 8.60E-02 0.001981872 
PCNA 4.57E-05 7.32E-02 0.001973239 
CCL19 4.46E-04 2.02E-02 0.001939058 
SRXN1 1.17E-02 7.35E-01 0.001855749 
TGFB1 1.17E-02 4.03E-03 0.001811702 
RPS9 9.12E-02 1.55E-01 0.001797939 
CCBL2 8.55E-03 8.17E-01 0.00178486 
IL18 3.43E-02 6.63E-03 0.001621556 
TLR3 4.57E-05 2.25E-03 0.001597187 
CAT 1.17E-02 1.06E-02 0.001440789 
CXCL12 4.39E-03 7.08E-01 0.001240178 
STAT5A 4.46E-04 5.87E-03 0.001212507 
CCL4L1 4.43E-04 NA 0.001154275 
CYBA 8.68E-04 6.63E-03 0.001124932 
COMT 2.66E-02 3.10E-03 0.001083953 
TJP2 1.82E-01 1.82E-02 0.001023283 
APOBEC3G 4.31E-04 4.01E-01 0.000973043 
DES 4.46E-04 9.57E-01 0.000931278 
IL1B 3.86E-03 6.56E-01 0.000919173 
SOCS1 4.43E-04 3.25E-01 0.000917126 
CCR1 1.83E-04 5.87E-03 0.000905665 
MMP2 9.99E-04 7.36E-04 0.000899559 
TLR1 1.37E-03 6.74E-02 0.000895813 





PDGFA 2.74E-01 1.82E-02 0.00086899 
TGFB3 9.12E-02 8.17E-01 0.000857405 
TYK2 5.48E-04 1.61E-04 0.000820597 
EDN1 4.39E-03 2.24E-02 0.000809721 
GZMB 4.46E-04 1.87E-03 0.000760621 
CCR5 4.40E-04 1.18E-02 0.000755522 
CD16 4.43E-04 NA 0.000734899 
TBXAS1 4.40E-04 3.61E-01 0.000725665 
PTPRC 4.46E-04 1.32E-02 0.000725176 
FAS 4.46E-04 2.73E-02 0.000691356 
CD4 5.04E-03 3.43E-01 0.000687411 
TLR8 4.46E-04 9.29E-01 0.000670881 
CCL24 1.55E-02 4.86E-01 0.000657373 
TNFRSF10B 4.46E-04 4.42E-01 0.000650675 
PDLIM1 2.46E-03 1.32E-06 0.000639734 
GSTZ1 3.06E-03 7.35E-01 0.000639177 
SELE 6.04E-04 2.06E-03 0.000637933 
MKI67 4.28E-04 8.17E-01 0.000597115 
TP53 4.57E-05 5.67E-03 0.000572586 
KMO 4.40E-04 6.56E-01 0.000568687 
TLR6 2.90E-03 7.08E-01 0.00054887 
CCL5 6.16E-04 1.06E-02 0.000529295 
PRDX4 2.63E-02 4.64E-01 0.000511853 
TNFRSF10A 1.83E-04 5.32E-01 0.000494198 
GSR 7.53E-02 1.18E-02 0.000469111 
ALOX5 1.59E-03 6.00E-01 0.000440451 
IFNB1 4.31E-04 9.71E-01 0.000427732 
TNFA 4.25E-04 NA 0.000416894 
HMBS 2.63E-02 3.31E-02 0.000409937 
IL6 4.34E-04 4.04E-03 0.000376125 
OGT 5.15E-01 7.32E-02 0.000366476 
TLR7 1.20E-01 4.70E-01 0.000348253 
IL7 4.40E-04 1.61E-04 0.000342663 
NGF 6.22E-03 6.30E-01 0.000333833 
CCL7 4.40E-04 6.30E-01 0.000321639 
CXCR4 2.16E-03 5.22E-02 0.000316939 
GSS 4.50E-01 8.45E-01 0.000295468 
CD69 6.04E-04 2.47E-02 0.000291231 





TNFSF10 4.03E-02 1.32E-02 0.000254065 
GPX7 6.62E-03 5.51E-01 0.000225074 
QPRT 1.68E-01 1.56E-03 0.000200203 
MMP9 3.22E-03 9.86E-01 0.000180675 
MPV17 7.53E-02 6.56E-01 0.000179366 
TLR5 2.34E-02 3.10E-03 0.000168241 
SLC2A1 8.39E-03 2.87E-02 0.000168083 
EGF 2.07E-02 3.10E-03 0.000166419 
CNTF 2.30E-01 8.17E-01 0.000152269 
CCL11 8.56E-03 6.30E-01 0.000128756 
CCR2 1.09E-03 9.43E-03 0.000123929 
IL4 2.92E-02 2.59E-01 0.000118935 
PLA2G6 1.55E-01 2.29E-01 0.000114646 
IL13 7.59E-03 8.45E-01 0.000112405 
DGCR8 7.22E-01 1.34E-04 9.84E-05 
SELP 4.98E-02 3.61E-01 9.81E-05 
PDGFB 1.20E-01 8.60E-02 9.77E-05 
NOS2 9.09E-02 4.21E-01 9.29E-05 
TDO2 4.04E-02 1.53E-01 8.30E-05 
CCL20 7.28E-03 2.72E-03 6.16E-05 
FASLG 3.57E-02 6.56E-01 5.80E-05 
CD8B 2.88E-02 5.09E-01 5.67E-05 
XCL1 1.55E-01 8.45E-01 5.65E-05 
IFNG 9.59E-03 2.74E-01 5.37E-05 
MBL2 8.13E-02 1.43E-01 5.25E-05 
IFNA1 5.34E-01 9.86E-01 4.38E-05 
LIN28A 1.41E-01 1.55E-01 4.38E-05 
GPR35 1.40E-01 1.78E-01 4.28E-05 
CCR7 1.41E-03 2.90E-01 4.03E-05 
PTGES 1.67E-01 5.69E-02 3.68E-05 
IL17F 2.28E-02 2.29E-01 3.50E-05 
SDHA 8.29E-01 3.07E-01 3.31E-05 
IL27 1.52E-01 1.78E-01 2.76E-05 
ALOX15B 3.49E-01 4.37E-02 2.68E-05 
IL25 5.33E-01 2.29E-01 2.48E-05 
IL12A 6.61E-02 2.90E-01 2.44E-05 
NTF4 2.08E-01 NA 2.34E-05 
IL29 3.06E-01 NA 2.05E-05 





ASMT 5.03E-01 5.56E-01 1.86E-05 
CXCR3 2.65E-01 1.08E-01 1.52E-05 
IL2 5.61E-01 7.08E-01 1.12E-05 
AGER 2.12E-01 1.00E-01 1.07E-05 
PTGS2 4.09E-02 7.95E-02 9.72E-06 
IL10 3.47E-01 9.86E-01 9.20E-06 
SLC6A3 2.76E-01 1.08E-01 8.67E-06 
NOX5 6.23E-01 6.30E-01 2.79E-06 
ALOX12 4.76E-01 8.45E-01 1.40E-06 
IL4I1 8.24E-01 2.73E-02 1.16E-06 
CD3D 4.77E-01 1.17E-01 -3.09E-07 
AANAT 7.89E-01 4.01E-01 -1.56E-06 
IL11 6.22E-01 9.29E-01 -1.91E-06 
IL12RB2 8.24E-01 6.56E-01 -2.13E-06 
CSF2 9.29E-01 8.73E-01 -2.17E-06 
SLC6A4 9.29E-01 9.86E-01 -2.62E-06 
TLR9 9.64E-01 4.37E-02 -5.73E-06 
TH 6.56E-01 2.02E-01 -6.01E-06 
TPH2 5.93E-01 6.56E-01 -6.91E-06 
IL8RA 1.00E+00 NA -7.60E-06 
PTGIS 9.64E-01 8.73E-01 -7.67E-06 
GDNF 8.94E-01 4.86E-01 -8.89E-06 
MPL 8.59E-01 6.56E-01 -1.07E-05 
STAT5B 1.00E+00 9.30E-02 -1.07E-05 
EPO 7.88E-01 5.32E-01 -1.20E-05 
MMP7 2.27E-01 5.04E-01 -1.48E-05 
FOXP3 4.76E-01 4.64E-01 -1.49E-05 
PF4 1.29E-01 7.35E-01 -1.55E-05 
MPO 6.56E-01 4.01E-01 -1.74E-05 
AOX1 2.26E-01 9.57E-01 -1.75E-05 
THPO 9.29E-01 9.29E-01 -1.93E-05 
CCL1 3.25E-01 3.20E-01 -1.98E-05 
PLA2G2A 8.06E-02 6.52E-02 -2.06E-05 
CCR3 3.25E-01 7.89E-01 -2.07E-05 
CLEC4C 3.97E-01 5.09E-01 -2.23E-05 
IL17A 7.20E-01 8.85E-01 -2.62E-05 
CCR4 2.83E-01 9.86E-01 -2.69E-05 
VEGFA 8.59E-01 1.00E+00 -3.64E-05 





ARG1 1.18E-01 2.74E-01 -3.90E-05 
IL12B 8.14E-02 5.56E-01 -4.26E-05 
TPO 4.22E-01 5.09E-01 -4.37E-05 
IDO2 6.02E-02 5.56E-01 -4.42E-05 
DAO 2.85E-01 2.02E-01 -4.64E-05 
CYP1A1 2.66E-01 7.62E-01 -5.22E-05 
ARG2 5.73E-01 1.17E-01 -5.67E-05 
CHRNA7 7.56E-01 NA -6.52E-05 
VEGFC 7.56E-01 5.32E-01 -6.54E-05 
TNRC6A 7.62E-01 4.78E-02 -6.82E-05 
NTF3 6.17E-02 3.07E-01 -7.91E-05 
EIF2C2 8.97E-01 NA -8.03E-05 
TBP 5.94E-01 9.01E-01 -8.65E-05 
TGFA 4.49E-01 4.01E-01 -8.70E-05 
PDGFC 9.65E-01 1.82E-02 -8.86E-05 
PDGFD 1.81E-01 7.62E-01 -9.53E-05 
ALOX15 8.09E-02 4.01E-01 -0.000127142 
HAAO 4.23E-01 1.08E-01 -0.000152081 
TARBP2 2.86E-01 1.55E-01 -0.000173737 
PRDX3 9.65E-01 9.29E-01 -0.000191979 
PTGS1 1.85E-02 3.43E-01 -0.000202329 
VEGFB 3.15E-01 6.74E-02 -0.000223901 
CAMK2D 9.65E-01 7.94E-02 -0.000228758 
CCBL1 6.89E-01 7.35E-01 -0.000229115 
CCS 4.08E-02 4.58E-03 -0.000246011 
TRIM32 6.89E-01 5.80E-01 -0.000251882 
TXNRD2 2.47E-01 1.64E-02 -0.000283047 
TPH1 8.31E-02 3.43E-01 -0.000330341 
AADAT 4.44E-03 6.05E-01 -0.000381198 
GLS2 1.46E-01 7.89E-01 -0.000386027 
BDNF 7.22E-01 9.28E-01 -0.000522046 
PTGES2 1.42E-01 1.00E+00 -0.000679475 
DICER1 6.22E-03 3.54E-03 -0.000735301 
CHRNA4 1.01E-01 1.53E-01 -0.00076971 
CNOT8 1.37E-03 2.15E-01 -0.001111782 
EIF2C1 2.05E-02 NA -0.001121491 
TJP1 3.60E-01 4.55E-04 -0.001614356 
GOT2 8.55E-03 1.45E-01 -0.001634541 





DROSHA 2.05E-02 6.56E-01 -0.00169264 
CX3CR1 4.34E-02 2.74E-01 -0.002187448 
GLUD1 1.46E-01 6.05E-01 -0.002279373 
PRDX2 1.83E-04 9.01E-01 -0.002399655 
CHRNB2 1.60E-03 3.07E-01 -0.002428287 
STK25 2.03E-01 1.78E-01 -0.002452983 
GOT1 4.57E-05 5.32E-01 -0.002750809 
CAMK2G 2.05E-02 4.21E-01 -0.003074029 
CX3CL1 3.60E-01 9.86E-01 -0.003219831 
TUBB3 5.45E-02 4.64E-01 -0.003931965 
HPRT1 2.06E-03 5.09E-01 -0.005920692 
RPL13A 4.60E-01 7.94E-02 -0.006246049 
CAMK2B 1.01E-01 4.70E-01 -0.007263731 
PRNP 1.46E-01 7.08E-01 -0.007819734 
GLS 9.14E-05 5.80E-01 -0.009282091 
RBFOX3 4.34E-02 9.86E-01 -0.00934925 
PTGDS 6.33E-01 4.86E-01 -0.010164182 
ENO2 3.06E-03 5.32E-01 -0.013313325 
SYP 5.48E-04 1.00E+00 -0.014818987 
CAMK2A 1.01E-01 7.08E-01 -0.016681366 
DLG4 5.45E-02 8.73E-01 -0.016972488 
GAPDH 8.55E-03 3.25E-01 -0.022098575 
APP 8.68E-04 5.32E-01 -0.027132085 
YWHAZ 1.37E-03 7.35E-01 -0.040272758 
TSPAN7 6.22E-03 4.42E-01 -0.054687197 
MBP 2.37E-01 6.30E-01 -0.057582173 
SNAP25 2.66E-02 2.15E-01 -0.063145012 
















Supplemental Table 5-1. Genes from the pigtailed macaque Nanostring panel PC1 
projected into the HIV encephalitis microarray panel that had a weight greater than or 
less than zero. Weights closer to +1 or -1 have the strongest effect in the sample separation 
in the projection. Because the HIVE samples separated higher than the uninfected samples, 
genes with a positive PC weight have the strongest effect. Similar to the SIV PC1, B2M, 
GFAP, and SOD2 have the strongest weight in separating HIVE from uninfected samples. 
NAs indicate genes that were not included in the HIV microarray panel. The red to blue 
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Johns Hopkins School of Medicine, Baltimore, MD 
Graduate Student Thesis Project 
•  The Immunoregulatory Role of Microglial CSF1R in the SIV Model of HIV CNS 
Disease 
o Tracked alterations in CSF1R and TREM2 mRNA and protein expression in 
the CNS throughout disease progression including latency. 
o Characterized viral dynamics and microglial cell biology in vitro (primary cell 
culture) and in vivo (NHP). 
o Developed and executed an RNA-Seq transcriptome-based project to 
characterize dysregulation of microglial and astrocyte immune activation and 
its impact on neurodegeneration in this model. 
o Designed and completed a pilot pre-clinical drug trial with PLX3397 (CSF1R 
inhibitor) in SIV-infected pigtailed macaques.  
Graduate Student Rotation Projects 
• Development of an Anti-Viral IgE screen from patient serum 
o Developed an IgE capture technique to be used with viral Phage 
Immunoprecipitation (PhIP) sequencing; used this capture technique to 
develop an ELISA to measure IgE levels in human serum.  
o Analyzed anti-viral IgE from patients with peanut allergy and asthma 
• Development of an Anti-Prostate Cancer Virus-Like-Particle Vaccine 
o Cultured VLPs and conjugated prostate cancer antigens; injected conjugated 











NIH R25 Pilot Grant: 2018; Translational Research in NeuroHIV and Mental Health 
Title: Dysregulation of central nervous system glial immune responses in a cART-suppressed 
SIV/macaque model of chronic HIV CNS disease 
Role: Principal Investigator 
Amount: $20,000; 1 year 
 
Publications 
Knight AC, Brill SA, Solis CV, Richardson MR, McCarron ME, Queen SE, Bailey CC, 
Mankowski JL. “Differential Regulation of TREM2 and CSF1R in CNS Macrophages in an 
SIV/Macaque Model of HIV CNS Disease.” J Neurovirol. Submitted 4 December 2019. 
 
Knight AC, Brill SA, Queen SE, Tarwater PM, Mankowski JL. “Increased Microglial 
CSF1R Expression in the SIV/Macaque Model of HIV CNS Disease.” J Neuropathol Exp 
Neurol. 2018. PMID: 29319808 
 
Mangus LM, Weinberg RL, Knight AC, Queen SE, Adams RJ, Mankowski JL. “SIV-
Induced Immune Activation and Metabolic Alterations in the Dorsal Root Ganglia During 
Acute Infection.” J Neuropathol Exp Neurol. 2018. PMID: 30500918 
 
Yokoya K, Zettler LW, Kendon JP, Bidartondo MI, Stice AL, Skarha S, Corey LL, Knight 
AC, Sarasan V. “Preliminary findings on identification of mycorrhizal fungi from diverse 
orchids in the Central Highlands of Madagascar.” Mycorrhiza. 2015. PMID: 25771863 
 
Presentations 
Conference on Retroviruses and Opportunistic Infections; 2020 
Poster presentation: “CSF1R Inhibition Targets CNS Macrophages in an SIV/Macaque 
Model of HIV CNS Disease.” 
 
NeuroHIV Lecture Series; 2019 
Invited talk: “Markers of Microglial Priming in an SIV/Macaque Model of HIV CNS 
Disease.” 
 
Society for NeuroImmune Pharmacology Annual Meeting; 2019 
Poster Presentation: “Differential Regulation of TREM2 and CSF1R in CNS Macrophages in 
the SIV/Macaque Model.” 
 
International Symposium on Neurovirology; 2019, 2018 
2019 Poster Presentation: “TREM2 and CSF1R as markers of chronic CNS inflammation in 
an SIV pigtailed macaque model of HIV CNS disease” 
2018 Oral and Poster Presentation: “TREM2 Expression Increases with SIV Encephalitis in a 
Macaque Model of HIV CNS Disease” 
 






Poster presentation: “Increased Microglial CSF1R Expression in the SIV/Macaque Model of 
HAND” 
 
The Johns Hopkins School of Medicine Pathology Young Investigators Day; 2018 
Poster presentation: “TREM2 expression increases with SIV encephalitis in a macaque 
model of HIV CNS disease.” 
 
Pathobiology Graduate Program Retreat 
2019 Invited Oral Presentation: “The Role of CSF1R in an SIV/Macaque Model of HIV CNS 
Disease” 
2018 Poster: “The Discordant Regulation of TREM2 and CSF1R in an SIV/Macaque Model 
of HIV CNS Disease” 
2017 Poster: “Increased Microglial CSF1R Expression in the SIV/Macaque Model of 
HAND” 
2016 Poster: “Heme Oxygenase-1 Expression in SIV+ Pigtailed Macaques” 
Awards 
New Investigator Scholarship; Conference on Retroviruses and Opportunistic Infections, 
2020 
Early Career Investigators in Training Travel Scholarship; International Symposium on 
Neurovirology, 2018 




New Investigator Scholarship; Conference on Retroviruses and Opportunistic Infections, 
2020 
Early Career Investigators in Training Travel Scholarship; International Symposium on 
Neurovirology, 2018 




Teaching, Mentorship, and Leadership Experience 
 
Baltimore Montessori Public Charter School Science Education; 2019-2020 
• Worked with Dr. Carlo Colantuoni to develop lesson plans for multiple sections of 
science education for 4th and 5th grade students; topics covered the big bang, 
evolution, comparative anatomy, cell biology, and genetics. 
• Executed these lessons in the classroom starting in December and will continue 
through the spring. 
Mentorship of Undergraduate Summer Student; 2019 
• Developed a research project for the student characterizing and quantifying PU.1 
protein expression in the SIV/macaque model. 
• Worked one-on-one with the student training her in different laboratory techniques, 
how to find and read the relevant literature, and how to analyze data. I also provided 
career advice and guidance. 





• Participated in a three-day intensive course focused on preparing PhD-level scientists 
for teaching at the undergraduate level. Activities included basic pedagogy, teaching 
strategies, flipped-classroom design, and syllabus generation. 
Teaching in Pathobiology: Pathobiology for Graduate Students, Basic Mechanisms 
Teaching Assistant; 2016 
• Presented a mini-lecture on basic infectious disease immunohistochemistry. 
• Assisted the class proctor with grading, facilitating in-class discussions, and 
answering student questions. 
Co-organizer of the Johns Hopkins Pathobiology Sabin Pathology Club; 2017 - 2019 
• Organized meeting topics and presenters in several-month rotating shifts. 
• Presented lectures on various pathology topics including autoimmune 
cardiomyopathy and neurotropic viruses 
Admissions Committee Member; 2017 and 2018 admissions cycle 
Undergraduate Teaching Experience; Illinois College 
• Student director of the Campus Writing Center; 2012-2014 
o Apprentice Coordinator; 2011-2012: Designed and executed a training 
program for Writing Center Consultants 
o Writing Center Consultant; 2011-2014: Assist peers through the writing 
process 
• Teaching Assistant: Genetics; Introduction to Physics II 
o Taught one class per week for each course; class focus was on working 
through problem sets and reviewing the course material from the previous 
week 
 
 
 
 
 
  
 
